LES RENCONTRES INTERNATIONALES DE BIOTECHNOLOGIES 20ov-leem.ovh › sites › default › files › RIB_Programm_2018_2.pdf · Bpifrance propose aux entreprises un continuum de financements

LES RENCONTRESINTERNATIONALES

DE BIOTECHNOLOGIES2018

Program / Programme. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

9:30

10:00

10:05 - 10:35

10:35 - 11:05

11:05 - 11:25

11:25 - 12:15

12:15 - 12:45

12:45 - 14:00

14:00 - 18:00

Morning coffee / Petit déjeuner

RIB opening / Ouverture Nicolas Dufourcq > BpiFrance general director & Philippe Lamoureux, Leem general director.

First session / Première session Sylvain Forget > Founder. BlueDil. www.bluedil.fr• NANOBIOTIX• GLIOCURE• ELYSSAMED• INOVACTIS

Second session / Deuxième session Manuel Gea > CEO. Bio Modeling System. www.bmsystems.net• STIMUNITY• IMCHECK• AFFILOGIC

Coffee break / Pause café

Third session / Troisième session Annick Schwebig > President. Essec Executive Board. www.essec.edu/fr• GAMAMABS• B-CELL DESIGN• THERAVECTYS• HALIODX

Fourth session / Quatrième session Christian Deleuze > RIB Managing director. www.leem.org/rib2018• NOVADISCOVERY• H-IMMUNE• THERACLION

Lunch break / Déjeuner

B to B meetings / Rencontres B to B

LES RENCONTRES INTERNATIONALES DE BIOTECHNOLOGIES 2018 • 3 2 • LES RENCONTRES INTERNATIONALES DE BIOTECHNOLOGIES 2018

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Les TPE/PME contribuent pour une large part au dynamisme du secteur de la santé : 45 % des entreprises ont moins de 200 salariés et emploient plus de 7 % des effectifs de l’industrie pharmaceutique.

Dans le foisonnement des sources d’informations et des offres de services sur internet, les TPE/PME ont du mal à obtenir des réponses claires aux questions concernant le développe-ment de leur société : comment analyser mon marché ? Quels types de financement public demander ? Quels outils existent pour accompagner ma croissance ? Quel est le coût réel d’un salarié recruté ? Quelle réglementation d’un produit sous Autorisation Temporaire d’Uti-lisation ?... Avec le Hub PME, les TPE/PME de la santé, qu’elles soient matures, en croissance ou tout juste créées, disposent désormais de réponses à l’ensemble des questions qu’elles se posent en termes de gestion, d’emploi, de réglementation ou de financement. Ce nouvel outil imaginé par le Leem centralise plus de 130 questions et leurs réponses. Près de 10 partenaires se sont associés au Leem dans le cadre du hub, parmi lesquels Pôle emploi, la Banque Publique d’Investissement (BpiFrance), la Chambre de Commerce et d’Industrie (CCI), les pôles de compétitivité et l’Opca défi.

www.hubpme.leem.org/

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Who is Leem?Leem is the French industry association which represents drug companies operating in France.

Representing and defending the pharmaceutical industryLeem has over 260 member companies representing a total workforce of 98,690 employees (more than 3% of industrial employment in France) and a revenue of more than €54.5 billion (of which half are exports). The industry association provides its members with in-depth, quantified and well-reasoned studies and analyses on the major issues facing the industry and on current events.On a national level, Leem acts as a champion and advocate for the pharmaceutical industry. In this capacity, it participates in numerous official, ministerial and inter-ministerial committees. Leem is a member of the French Federation of Healthcare Industries (FEFIS) and of the French Enterprise Movement (MEDEF). At international level, Leem is a member of the European Federation of Pharmaceutical Associations and Industries (EFPIA) and of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), to which Leem’s Direc-tor General was appointed as Vice-President in May 2017.

Engaging in agreement-based policy with the StateEvery three years since 1994, Leem has negotiated the agreement-based policy with the State for the price setting and regulation of medicines in France through a «framework agreement». The latest policy, signed in January 2016, provides the government and pharmaceutical com-panies with a solid basis to address the issue of innovative treatment pricing.As the interlocutor between industry and policy makers, Leem is the driving force behind proposals to promote France’s attractiveness as an industrial hub and to pursue a healthcare policy geared towards patients’ needs, while preserving the benefits delivered by innovative therapies as well as the healthcare spending control target. Qu’est-ce que le Leem ?Le Leem est l’organisation professionnelle des entreprises du médicament opérant en France.

Représenter et défendre l’industrie du médicamentLe Leem compte plus de 260 entreprises adhérentes qui représentent un effectif global de 98 690 salariés (plus de 3% de l’emploi industriel en France) et un chiffre d’affaires de plus de 54,5 milliards d’euros (dont la moitié à l’exportation). L’organisation professionnelle met à disposition de ses adhérents des études et analyses approfondies, chiffrées et argumentées liées aux grands enjeux du secteur et à l’actualité. Le Leem, pilote, à l’échelon national, les actions de défense collective et de valorisation de l’industrie du médicament. A ce titre, il par-ticipe à de nombreuses commissions officielles, ministérielles et interministérielles.Le Leem est membre de la Fédération Française des Industries de Santé (FEFIS) et du Mouve-ment des Entreprises de France (MEDEF). Au niveau international, le Leem siège à la Fédéra-tion Européenne d’Associations et d’Industries Pharmaceutiques (EFPIA) et à l’International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) dont la vice-présidence est assurée par le directeur général du Leem depuis mai 2017.

Conduire la politique conventionnelle avec l’EtatDepuis 1994, le Leem négocie tous les 3 ans avec l’Etat la politique conventionnelle de fixation et de régulation des prix des médicaments en France au travers d’un «accord-cadre ». Le dernier, signé en janvier 2016, fournit aux pouvoirs publics et aux industriels du médicament une base solide pour appréhender la problématique des prix des traitements innovants.Interlocuteur des décideurs politiques, le Leem se veut force de propositions pour promouvoir l’attractivité industrielle de la France et conduire une politique de santé axée sur les besoins des patients qui tienne à la fois compte du retour des innovations thérapeutiques et de l’objec-tif de maîtrise des dépenses de santé.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Un guichet uniqueà l’initiative du Leem :

le HUB PME


Aide à l’innovation

> Subvention21 M€ pour 239 projets

Aide à l’innovation48,8 M€ 135 Projets

> Avance récupérable29,8 M€ pour 88 projets

> Prêt à Taux Zéro19 M€ pour 47 projets

Concours d’Innovation Numérique11,7 M€ pour 28 projetsAmbition «mieux vivre

Concours Mondial d’Innovaion - Phase 2 19 M€ pour 14 projets : Silver économie et Médecine individualisée

Chiffres calculés sur la base des contrats signésSanté = pharma-bioindustrie / technologies médicales

Continuum de l’innovationFilière de la Santé 2017

187 M€ d’aides à l’innovation437 projets

Explorerla faisabilité

Réaliservos projets

… EnPartenariat

Industrialiservotre

Innovation

Renforcervos

fonds propres

26 M€80,3 M€

78 M€

7,6 M€

Projet Industriel d’Avenir7,6 M€ pour 2 projets

55,5 M€Fonds capital Innovation> Innobio> Maladies rares> FABS

2 nouveaux investissement :• Aelis Farma et Dynacure• 21 refinancement

Fonds PSIMLevée de fondsHalioDX 18 M€ Bioserenity 13 M€ Wandercraft 15 M€

Fonds Large Venture• 14 sociétés santé dans le portefeuille• 1 nouvel investissement : Doctolib • 1 IPO : Biom’up• 5 ré-investissements

Fonds UniqueInterministériel6 M€ pour 11 projets

Projets Structurant pour la Compétitivité72 M€ pour 8 projet

Financements issus des investissements d’avenir

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Bpifrance, a subsidiary of the French state and the Caisse des Dépôts and the entrepreneurs’ trusted partner, finances businesses from the seed phase to IPO, through loans, guarantees and equity investments. Bpifrance also provides operational services and strong support for innovation, export, and external growth in partnership with Business France and Coface.

Bpifrance offers to businesses a large range of financing opportunities at each key step of their development, including offers adapted to regional specificities. With its 42 regional offices (90% of decisions are made locally), Bpifrance represents a strategic tool for economic com-petitiveness dedicated to entrepreneurs. Bpifrance acts as a back-up for initiatives driven by the French State and the Regions to tackle 3 goals:

• Contribute to SME’s growth• Preparing tomorrow’s competitiveness• Contributing to the development of a positive entrepreneur ecosystem.

With Bpifrance, businesses benefit from a powerful, efficient and close representative, to ans-wer all their needs in terms of financing, innovation and investment.

More info @ www.bpifrance.fr - Follow us on Twitter : @bpifrance

Bpifrance, filiale de la Caisse des Dépôts et de l’État, partenaire de confiance des entrepre-neurs, accompagne les entreprises, de l’amorçage jusqu’à la cotation en bourse, en crédit, en garantie et en fonds propres. Bpifrance assure, en outre, des services d’accompagnement et de soutien renforcé à l’innovation, à la croissance externe et à l’export, en partenariat avec Business France et Coface.

Bpifrance propose aux entreprises un continuum de financements à chaque étape clé de leur développement et une offre adaptée aux spécificités régionales.

Fort de 42 implantations régionales (90 % des décisions prises en région), Bpifrance constitue un outil de compétitivité économique au service des entrepreneurs. Bpifrance agit en appui des politiques publiques conduites par l’État et par les Régions pour répondre à trois objectifs :

• Accompagner la croissance des entreprises ;• Préparer la compétitivité de demain ;• Contribuer au développement d’un écosystème favorable à l’entrepreneuriat.

Avec Bpifrance, les entreprises bénéficient d’un interlocuteur puissant, proche et efficace, pour répondre à l’ensemble de leurs besoins de financement, d’innovation et d’investisse-ment.

Plus d’information sur : www.bpifrance.fr - http://investissementsdavenir.bpifrance.fr/ - Twitter : @bpifrance

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


Les partenaires

Partners. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

About Medicen Paris RegionMedicen Paris Region is a competitiveness cluster for innovative health technologies, with national and international scope. With more than 300 companies, research centers, universities, hospitals and local authorities as members, it aims to position the Paris region as Europe’s leading healthcare cluster. It focuses on five strategic areas: biological diagnostics, diagnostic and interventional imaging, regenerative medicine and biomaterials, digital health and translational medicine. In close collaboration with local, regional and national healthcare innovation players, Medicen Paris Region aims to:• Foster the emergence, development and funding of certified collaborative projects in the healthcare

sector, in order to create economic value and jobs• Increase the international development of innovative startups and SMEs• Strengthen the attractiveness of the Paris region, which represents more than 50% of life sciences

activity in France

Since the creation of the cluster in 2005, 62 innovative products have been launched in the imaging, medical devices and biological tools sectors. The cluster has certified 292 projects. They received fun-ding from the French government (French Inter-Ministry Fund FUI, Structuring Projects fund), the public investment bank Bpifrance, the National Research Agency, the European Regional Development Fund, the Investments for the Future program and/or local authorities, and the Paris region. Total investment is close to €1.9 billion and €533 million of public aid.www.medicen.org

À propos de Medicen Paris Region Medicen Paris Region est un pôle de compétitivité des technologies innovantes en santé, à rayonnement national et international. Il mobilise plus de 300 entreprises, organismes académiques, hôpitaux et collec-tivités territoriales autour d’une même ambition : positionner l’Île-de-France en premier cluster de santé d’Europe. Son activité se concentre autour de cinq axes stratégiques : diagnostic biologique, imagerie diagnostique et interventionnelle, médecine régénératrice et biomatériaux, santé numérique ainsi que médecine translationnelle. En étroite collaboration avec les acteurs régionaux et nationaux de l’innovation en santé, la mission de Medicen Paris Region consiste à :• faire émerger, valoriser et aider au financement de projets collaboratifs labellisés en santé dans le but de

les transformer en valeur économique et en emplois• accélérer le développement économique de startups et PME innovantes à l’international• renforcer l’attractivité du territoire francilien, animer et catalyser cet écosystème représentant plus de

50% des sciences de la vie en France.

Depuis la création du pôle en 2005, 62 produits innovants ont été commercialisés dans les domaines de l’imagerie, des dispositifs médicaux et des outils biologiques. 292 projets ont été labellisés et financés par l’État (Fonds unique interministériel, Projets structurants), Bpifrance, l’Agence Nationale de Recherche, le Fonds Européen de Développement Régional, les Investissements d’Avenir et/ou par les collectivités territoriales, la Région Île-de-France. Cela représente un investissement total de 1,9 milliard d’euros et 533 millions d’euros d’aides publiques.www.medicen.org. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

EUROBIOMED is the catalyst of the health sector in the Provence-Alpes-Côte d’Azur and Languedoc-Roussillon regions. We provide resources and initiatives to help life science companies achieve their business goals and improve life through innovations in health. Founded in 2009 by regional stakeholders, EUROBIOMED tops European rankings in all stages of innovation: education, basic research, translational and clinical research, technological innovation centers, start-ups and manufacturing. Together, the 253 EUROBIOMED members from 200 different companies are a driving force in regional development (with 165 projects, representing 650 million EUR of investment and 700 direct jobs) and a source of solutions for millions of patients coping with serious conditions such as cancer, chronic inflammatory disease, infectious and (re)emerging diseases, neurological diseases, and rare diseases.EUROBIOMED provides resources and offers solutions for businesses and research organisations in the health sector to help them innovate, finance, develop and achieve their strategic and business objectives to ultimately improve the treatment and the lives of patients.Mission and Activities: Develop the sector in the South of France: networking of members, Representation of the sector to third parties (public authorities, international), Implementation of scientific and business eventsStructuring and financing of public-private R&D projects: Monitoring calls for projects, Identification of partners, Support for project formation and financing, Project follow-up to marketingPersonalised support for businesses: Strategic analysis, Financing – Fundraising, Commercial develop-ment and internationalisation, Regulatory compliance

EUROBIOMED est l’accélérateur du développement de la filière santé, depuis la recherche fonda-mentale jusqu’au marché, au bénéfice des patients et de l’économie du sud de la France. Fondé en 2009 par l’ensemble des acteurs de la filière santé des régions Provence Alpes Côte d’Azur et Languedoc-Roussillon, EUROBIOMED pointe au sommet des classements européens à toutes les étapes de la chaîne de l’innovation : enseignement, recherche fondamentale, translationnelle et clinique, centres d’innovation technologique, start-ups et success stories industrielles. Ensemble, les 253 membres du collectif EUROBIOMED (dont 200 entreprises) constituent non seulement un formidable moteur de développement régional (165 projets de R&D représentant 650 millions d’euros d’investissements et 700 emplois directs) mais aussi une source de solutions pour les millions de patients confrontés à des pathologies sévères : cancers, pathologies inflammatoires chroniques, maladies infec-tieuses, maladies (ré)émergentes, maladies neurologiques, maladies rares et orphelines. EUROBIOMED offre des ressources et propose des solutions dédiées aux sociétés et aux organismes de recherche de la filière santé pour les aider à innover, à se financer, à se développer et à atteindre leurs objectifs straté-giques et commerciaux pour, in fine, améliorer la prise en charge et la vie des patients.Développer la filière sur le sud de la France : Animation et mise en réseau des membres, Renforce-ment de l’écosystème, Développement de collaborations nationales et internationales, Représentation de la filière vis-à-vis de tous les tiers (pouvoir publics, international), Mise en œuvre d’événements scientifiques et business.Structurer et accompagner le financement de projets public-privé/de R&D : Veille sur les appels à projets, Identification de partenaires, Accompagnement au montage et au financement du projet, Suivi de projet jusqu’à la commercialisationProposer un accompagnement personnalisé aux entreprises : Analyse stratégique ; Financement – Aide à la levée de fonds ; Développement commercial et international ; Stratégie règlementaire ; Industrialisa-tion et productionEurobiomed est présidé par Xavier Tabary, et dirigé par Emilie Royere. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Created in 1997, France Biotech is a French non-for-profit organization that brings together the country’s leading innovative health companies and their expert partners. France Biotech’s primary mission is to support the development of this industry in France, by improving the tax, legal, regulatory and managerial environment in which these companies operate and by advocating for their recognition as a leading-edge industry. France Biotech also aims to turn French innovative health technologies into world leaders. The organization, which championed the creation of the French Young Innovative Company (JEI) status in 2004, develops a wide range of actions intended to set the innovative health sector on an independent and high-performance course. France Biotech is chaired by Maryvonne Hiance and has more than 170 members.www.france-biotech.fr

Créée en 1997, France Biotech est l’association française qui regroupe les principales entreprises inno-vantes de la santé et leurs partenaires experts. France Biotech a pour mission première d’accompagner le développement de cette industrie en France en améliorant l’environnement fiscal, juridique, réglementaire et managérial de ces entreprises afin qu’elle soit reconnue comme industrie de pointe prioritaire. France Biotech a également la vocation de contribuer à hisser l’industrie française des technologies innovantes de la santé au rang de leader mondial. A l’origine du statut de Jeune Entreprise Innovante (JEI), mis en place lors de la Loi de Finances de 2004, France Biotech milite pour que le secteur innovant de la santé représente une industrie performante à part entière. France Biotech est présidée par Maryvonne Hiance et compte plus de 170 membres.www.france-biotech.fr . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Located in the Essonne administrative department south of Paris, Genopole is one of Europe’s leading hubs for life sciences. Its mission is to contribute to the development and growth of innovative biotech-nologies that improve our health, living conditions and environment. Genopole has created a business accompaniment offer, unmatched in France, enabled by professional project managers, and adaptable to the size of the concerned company. Its 109,000 square meters of real estate is also malleable, with an offer ranging from creators’ offices or an incubator for young start-ups to the «hôtels d’entreprises» with larger offices and labs for more mature businesses.

Today, Genopole counts 19 public research laboratories (CEA, CNRS, Inserm, etc.), 86 biotech companies and 25 shared-use, cutting-edge technological platforms. Its primary development orientations are perso-nalized medicine, gene and cell therapies, and synthetic biology. The biocluster currently employs 2,475 people and aims to employ 6,000 by 2025. Several real-estate projects are underway to enable that goal and extend the biocluster’s scientific, technological and entrepreneurial environment.To learn more: www.genopole.fr and https://join-the-biocluster.genopole.fr/.

Genopole, situé dans le Grand Paris Sud (Essonne), est l’un des premiers clusters européens dédiés aux sciences de la vie. Sa mission est de contribuer à l’éclosion des innovations biotechnologiques qui amélioreront notre santé, nos conditions de vie et notre environnement. Genopole a instauré un accom-pagnement unique en France, soutenu par une équipe de chargés d’affaires et dimensionné selon la taille de l’entreprise accompagnée. Le parc immobilier de 109 000 m2 est lui-aussi adapté aux besoins de la société, du bureau créateur ou de la pépinière pour les jeunes pousses aux hôtels d’entreprises dotés de surfaces (bureaux et laboratoires) plus vastes pour les sociétés matures.

Le biocluster compte aujourd’hui 19 laboratoires de recherche publics (CEA, CNRS, Inserm…), 86 entre-prises de biotechnologie et 25 plates-formes techniques de pointe mutualisées. Ses principaux axes de développement sont la médecine personnalisée, les thérapies génique et cellulaire, la biologie de syn-thèse. 2475 personnes travaillent sur site. L’ambition est de porter cet effectif à 6000 d’ici 2025. Plusieurs projets immobiliers sont en cours pour étendre la capacité d’accueil du biocluster et son l’environnement scientifique, technologique et entrepreneurialPlus d’informations sur : www.genopole.fr et https://join-the-biocluster.genopole.fr/

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

The Cancéropôle Lyon Auvergne-Rhône-Alpes (CLARA), a cancer research cluster, is an initiative launched and funded by public authorities (French National Cancer Institute, regional authorities and the European Regional Development Fund). It is part of the French National Cancer Plans, and its purpose is to foster cancer research in the Auvergne-Rhône-Alpes region.Since 2003, CLARA has been bringing together academic, clinical and industry stakeholders from Au-vergne-Rhône-Alpes to advance regional, national and international strategies for cancer. Its goal is two-fold: rapid transfer of discoveries to patients and the commercial application of research.It has worked to energize and enrich cancer research by mobilizing the Auvergne-Rhône-Alpes area’s strengths in the field. This organizational effort aims to go beyond institutional, geographical, sectorial and subject-related barriers in order to synergize these strengths so as to more effectively conribute to the fight against cancer.

The entire Cancéropôle team looks forward to meeting you on April 3-4 for CLARA’s special 15th anniver-sary edition of its annual Cancer Research Forum, which will be punctuated by many highlights (scientific conferences, testimonials, business meetings, poster sessions).More information: www.canceropole-clara.com - twitter @canceroCLARA

Le Cancéropôle Lyon Auvergne-Rhône-Alpes (CLARA) est une initiative lancée et financée par les pouvoirs publics (Institut National du Cancer, Collectivités territoriales et le Fonds Européen de Développement Régional). Il s’inscrit dans le cadre des Plans Cancers nationaux et vise à développer la Recherche en oncologie en Auvergne-Rhône-Alpes.Depuis 2003, le CLARA fédère les acteurs académiques, cliniques et industriels d’Auvergne-Rhône-Alpes, au service d’une stratégie régionale, nationale et internationale de lutte contre le Cancer dans un double objectif: le transfert rapide des découvertes vers les patients et la valorisation économique de la recherche.Le CLARA développe également des actions en faveur de l’ouverture de la Recherche vers les sciences humaines et sociales et les questions de santé publique, mettant ainsi le patient au cœur de la Recherche.Outre son engagement auprès de l’ensemble des acteurs de la Recherche pour favoriser leur décloisonne-ment et les collaborations, le CLARA accompagne les projets par le biais d’une offre de services structurée et élaborée en adéquation avec leurs besoins.

Toute l’équipe du Cancéropôle vous attend les 3-4 avril prochains pour l’édition spéciale 15ème anniversaire du CLARA lors de son Forum annuel de la Recherche en Cancérologie ponctué par de nombreux temps forts (conférences scientifiques, témoignages, rendez-vous d’affaires, sessions posters).Plus d’information : www.canceropole-clara.com - twitter @canceroCLARA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

L’INNOVATION AU SERVICE DE LA LUTTE CONTRE LE CANCER

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

MabDesign is a French membership organization that aims to structure, federate, mobilize and support the development of the industrial sector in the field of immunotherapy. Its creation in 2014, comes from the joint will of four competitiveness clusters (Atlanpole Biotherapies, Eurobiomed, Lyonbiopole, Medi-cen) and three pharmaceutical companies (LFB, Pierre Fabre and Sanofi). Moreover,MabDesign is issued from governmental and health industry recommendations. MabDesign provides to its members strategic leverage and development opportunities.In order to accomplish its mission, MabDesign has implemented several actions. On the one hand, MabDesign has created a national smart directory of immunotherapy stakeholders, available online; orga-nizes several local and international scientific events per year with high-profile experts in the field; writes prospective reports on strategic topics for the industry; and builds technological cutting-edge training programs to keep the industry sector updated with the necessary skills to maintain competitiveness. On the other hand, MabDesign supports the economic development of the sector through services tailored to business, to optimize their marketing positioning, increase their fine knowledge of their market, maximize the protection and enhancement of their innovations, and conquer new international markets through support in business development. Finally, to promote the development and production of biomedicines on the territory, MabDesign is involved in various government actions dedicated to bioproduction.Operational since September 2015, MabDesign already 115 member companies, pharmaceutical and bio-technology industries, service providers, training organizations and equipment suppliers at the forefront of technological innovation.More information : www.mabdesign.fr I Twitter : @MabDesign_fr I [email protected]

MabDesign est l’association française de la filière industrielle de l’immunothérapie. Créée en 2014 par la volonté commune de quatre pôles de compétitivité (Atlanpole Biotherapies, Eurobio-med, Lyonbiopôle, Medicen) et de trois industriels (LFB, Pierre Fabre et Sanofi) dans le cadre d’un appel à projet « Filières Industrielles Stratégiques » issu du Programme d’Investissement d’Avenir (PIA), MabDe-sign ambitionne d’accompagner, structurer, fédérer et augmenter la visibilité de la filière industrielle de l’immunothérapie, de favoriser les échanges, de stimuler l’innovation et de favoriser le développement et le bioproduction d’immunothérapies sur le territoire. Pour accomplir sa mission, MabDesign a mis en place plusieurs actions. D’une part MabDesign a créé un annuaire national des acteurs de l’immunothérapie, disponible en ligne ; organise plusieurs fois par an des événements scientifiques nationaux ou internationaux de haut niveau ; rédige des documents de synthèse sur des sujets stratégiques pour la filière ; et élabore des formations continues spécialisées pour s’adap-ter aux évolutions de compétences nécessaires au maintien de la compétitivité des acteurs de la filière. D’autre part, MabDesign soutient le développement économique de la filière grâce à des services adaptés aux entreprises, pour optimiser leur positionnement marketing, accroître leur connaissance fine de leur marché, maximiser la protection et la valorisation de leurs innovations, et enfin conquérir de nouveaux marchés à l’international par un appui en business développement. Enfin, pour favoriser le développement et la production de biomédicaments sur le territoire, MabDesign est impliqué avec les services de l’Etat dans différentes actions gouvernementales autour de la bioproduction.Opérationnel depuis septembre 2015, MabDesign compte déjà 115 sociétés membres, aussi bien indus-triels pharmaceutiques ou de biotechnologie développeurs d’immunothérapies, prestataires de services, organismes de formation et fournisseurs de matériel à la pointe de la technologie. Plus d’information sur : www.mabdesign.fr I Twitter : @MabDesign_fr I [email protected]

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

MATWIN is a French nationwide programme supporting open-innovation in the dedicated field of onco-logy. The main objectives are to assess and support innovative projects with high transfer potential either coming from Academia or start-up, with the view of fostering early partnerships. This the process is based on public-private partnership with international laboratories (Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Genomic Health, GlaxoSmithKline, Janssen, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi) and the French research in oncology. Since 2015, MATWIN is a wholly owned subsidiary of UNICANCER group, gathering the 20 French Comprehensive Cancer Centers. As applicant to the MATWIN programme, projects have access to 3 steps action :• Double international assessment (academic and industrial) • Coaching to optimize projects structuring and industrial development potential• Access to MATWIN partners’ network (major groups, biotechs, investors) to foster early partnerships with a possible label of the International MATWIN Board.

Each year, MATWIN organizes also a European Partnering Convention called MEET2WIN entirely dedi-cated to open innovation and collaborative research in oncology. The 4th edition of MEET2WIN will take place in Bordeaux on May 17th & 18th, gathering 300 participants involved in oncology innovation around 1 000 B2B meetings slots, to optimize collaboration opportunities to fight cancer (programme / registration : www.meet2win.fr) More information on www.matwin.fr – Twitter @MATWIN_Bdx

MATWIN est un programme national français d’open-innovation et de soutien à la maturation de pro-jets en oncologie. Son objectif principal est d’expertiser et accompagner des projets innovants issus de laboratoires académiques ou portés par des startups et présentant un fort potentiel de développement industriel en favorisant des partenariats précoces. En ce sens, le process s’appuie sur un partenariat avec de grands laboratoires engagés en oncologie (Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Genomic Health, GlaxoSmithKline, Janssen, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi) et l’ensemble de la recherche française en cancérologie. Depuis 2015, MATWIN est une filiale à 100% d’UNICANCER (fédération rassemblant l’ensemble des Centres français de Luttre contre le Cancer).

En candidatant à MATWIN, les projets ont ainsi accès à :• une double expertise (académique et industrielle) de niveau international • un coaching personnalisé pour aider à optimiser la structuration et l’orientation industrielle du plan de développement R&D des projets• un accès à un réseau de partenaires (entreprises pharma & diag, biotechs, start-up, investisseurs, etc.) en recherche de projets à fort potentiel de transfert, avec une éventuelle labellisation du Board Interna-tional de MATWIN

Chaque année, MATWIN organise également une Convention Partnering européenne baptisée MEET2WIN entièrement dédiée à l’open innovation et à la recherche collaborative dans le domaine de l’oncologie. La 4ème édition de MEET2WIN aura lieu les 17 et 18 mai 2018 à Bordeaux et fédérera près de 300 acteurs de la chaîne de l’innovation en oncologie autour de 1 000 RV B2B pour optimiser les opportunités de colla-boration dans la lutte contre le cancer (programme / inscription : www.meet2win.fr) Plus d’informations sur www.matwin.fr – Twitter @MATWIN_Bdx

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

16 • LES RENCONTRES INTERNATIONALES DE BIOTECHNOLOGIES 2018

LES RENCONTRES INTERNATIONALES DE BIOTECHNOLOGIES 2018 • 19

Biotech companies have been selected on the basis of their research area, their scientific excel-lence and their will to forge collaborations with big pharmaceutical companies.

A joint independent committee has proceeded to their evaluation, based both on their written and oral presentations.

Les sociétés de biotechnologies ont été sélec-tionnées à la fois sur leur thématique de re-cherche, l’excellence de leur projet et leur volon-té de nouer des alliances avec des entreprises pharmaceutiques.

Un comité de sélection mixte et indépendant a évalué les sociétés candidates sur la base de leurs dossiers et de leurs présentations orales.

Selection committeeComité de sélection

Jean-Pierre Armand focuses his cancer research in the field of new mecha-nism of oncogenes’ and early drug development.

Jean-Pierre Armand MD, MSc, is certified in Medical Oncology (University of Toulouse III and Paris XI)

He was recently General Director of the Institut Claudius Regaud in Toulouse . Over the last five years he has been in charge of the construction of a new cancer center, in a European research hub created in the Toulouse cancer campus (Institut Universitaire du Cancer)and opened in 2014.

After a position as research fellow in Columbia University New York, Dr Ar-mand has joined Institut Claudius Regaud in Toulouse, he was head of Medical oncology until 1984. In the next 23 years, at Institut Gustave Roussy (IGR) in Paris, he was successively CEO of the Hospital IGR3, head of the Department of Medical oncology at IGR2 and finally CMO of IGR&D, Dept of Innovation and Development at IGR.

Although expert in breast, head&neck, and neuro-oncology, the first field of Dr Armand was very early drug development in phase 1 and 2 of new anticancer agents . He is the founder of the IGR Phase I Unit (Ditep) in the early 80s. He did the first in human phase I in the world at IGR of numerous drugs, now used routinely, including classicals cytotoxics,topo2 inhibitors, Irinotecan, Oxalipla-tin, Taxotere, Navelbine, Vinflunine, and more recently targeted therapies, Sutent, Sorafenib, Temsirolimus...

At present ,he and his colleagues are concentrating in Gustave Roussy DITEP on new therapies for orphan treatment cancer diseases, with a special perso-nal investment in cancer biotechs .

Dr Armand is active in the International Cancer community.He served as :• President of the European Society for Medical Oncology (ESMO), • President of the French Cancer Society (SFC) Medical Director of the Fede-

ration of European Cancer Societies (FECS/ECCO)• Chairman of the Protocol Review Committee of European Organization of

Research and Treatment of Cancer (EORTC)• Chairman of Oncology at French EMA (AFSSAPS)• Member of International Boards of the American Association for Cancer

Research (AACR)• Member of scientific committee of the American Society of Clinical Onco-

logy (ASCO) and AACR• Member of the board of clinical trials at Institut National du Cancer (INCa)• chairman of the president nominating committee of ESMO

He is member of the Chinese Society of Medical Oncology (CSCO).

Dr Jean-Pierre ARMAND is also proud to have been a mentor and teacher of multiple students, medical oncology fellows from all over the cancer world.

Jean-Pierre ARMAND. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

He has (co)authored over 300 medical and scientific peer-reviewed articles and he is/was member of the Editorial Boards of Annals of Oncology, the European Journal of Cancer, Journal of Clinical Oncology, Investigational New Drugs, Anticancer Research, Clinical Cancer Research.,CISCO journalDr Armand he received In 2008 (Stockholm) the ESMO Award as “the European oncologist of the year”.

• In 2013 the Targeted Anticancer Therapy (TAT) honorary award in recogni-tion of his contribution to new drug discovery in cancer

• In 2014 the European Lung cancer award in Athens• he is Chevalier of French Legion d honneur

After a 5 years as CEO of Institute Claudius Regaud in Toulouse, he is now (2015) back in Paris as senior consultant in the drug development department (DITEP) at Institute GUSTAVE ROUSSY and Chief Medical Strategy Officer at Cancer campus Grand Paris.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Before joining Inserm Transfert, Pascale had led Institut Pasteur’s Techno-logy Transfer and Entrepreneurship office since 2011. She has more than 15 years’ experience in the fields of technological innovation in life science and health technology, research transfer and entrepreneurship, and the biotech-nology start-up industry.

She headed business development at Neurotech, Entomed and AB Science then operational strategy in the sciences and health technology, and ran Ernst & Young activities in France. She also chaired the evaluation commit-tee reviewing “high-market-potential products, technologies or services” at France’s Agence Nationale de la Recherche from 2008 to 2011. Pascale Augé holds a doctorate in molecular pharmacochemistry, experimen-tal pharmacology and metabolism from Université Paris V, and a chemical engineering degree from the École de Chimie de Strasbourg.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Pascale AUGÉPrésidente du directoire d’Inserm transfert

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


Jean-Pierre Armand focuses his cancer research in the field of new mecha-nism of oncogenes’ and early drug development.

Jean-Pierre Armand MD, MSc, is certified in Medical Oncology (University of Toulouse III and Paris XI)

He was recently General Director of the Institut Claudius Regaud in Toulouse. Over the last five years he has been in charge of the construction of a new cancer center, in a European research hub created in the Toulouse cancer campus (Institut Universitaire du Cancer)and opened in 2014.

After a position as research fellow in Columbia University New York, Dr Ar-mand has joined Institut Claudius Regaud in Toulouse, he was head of Medical oncology until 1984. In the next 23 years, at Institut Gustave Roussy (IGR) in Paris, he was successively CEO of the Hospital IGR3, head of the Department of Medical oncology at IGR2 and finally CMO of IGR&D, Dept of Innovation and Development at IGR.

Although expert in breast, head&neck, and neuro-oncology, the first field of Dr Armand was very early drug development in phase 1 and 2 of new anticancer agents . He is the founder of the IGR Phase I Unit (Ditep) in the early 80s. He did the first in human phase I in the world at IGR of numerous drugs, now used routinely, including classicals cytotoxics,topo2 inhibitors, Irinotecan, Oxalipla-tin, Taxotere, Navelbine, Vinflunine, and more recently targeted therapies, Sutent, Sorafenib, Temsirolimus...

At present ,he and his colleagues are concentrating in Gustave Roussy DITEP on new therapies for orphan treatment cancer diseases, with a special perso-nal investment in cancer biotechs .

Dr Armand is active in the International Cancer community.He served as :• President of the European Society for Medical Oncology (ESMO), • President of the French Cancer Society (SFC) Medical Director of the Fede-

ration of European Cancer Societies (FECS/ECCO)• Chairman of the Protocol Review Committee of European Organization of

Research and Treatment of Cancer (EORTC)• Chairman of Oncology at French EMA (AFSSAPS)• Member of International Boards of the American Association for Cancer

Research (AACR)• Member of scientific committee of the American Society of Clinical Onco-

logy (ASCO) and AACR• Member of the board of clinical trials at Institut National du Cancer (INCa)• chairman of the president nominating committee of ESMO

He is member of the Chinese Society of Medical Oncology (CSCO).

Dr Jean-Pierre ARMAND is also proud to have been a mentor and teacher of multiple students, medical oncology fellows from all over the cancer world.

Alain Beck is Senior Director of Analytical Chemistry, New Biological Entities, at the Center of Immunology Pierre Fabre (FR), associated editor of mAbs (USA) and mAbDesign AB chairman (FR). He has contributed to the R&D of immune-oncology mAbs, clinical stages mAbs and ADCs in oncology (dalo-tuzumab licensed to Merck; telisotuzumab vedotin, licensed to AbbVie and h515H7), peptides and vaccines (RSV, ELA/P40). He has published more than 190 papers and reports on mAbs, biosimilars, biobetters, ADCs, bsAbs, Fc-fusion, protein scaffolds structure/function relationships and developability.

He was involved in more than 230 scientific meetings (AIS, ASMS, BAS, CASSS, EAC, HPLC, IBC, IMSC, PEGS, SEP, WADC, WBC) as chairperson, invited keynote speaker, panelist, moderator, advisor, and organizer as well as to meetings and workshops with regulatory agencies (ANSM, EMA, EDQM, FDA, PEI, WHO).

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Jean-Christophe BARLAND. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Alain BECKSenior Investmant Manager

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

He has (co)authored over 300 medical and scientific peer-reviewed articles and he is/was member of the Editorial Boards of Annals of Oncology, the European Journal of Cancer, Journal of Clinical Oncology, Investigational New Drugs, Anticancer Research, Clinical Cancer Research.,CISCO journalDr Armand he received In 2008 (Stockholm) the ESMO Award as “the European oncologist of the year”.

• In 2013 the Targeted Anticancer Therapy (TAT) honorary award in recogni-tion of his contribution to new drug discovery in cancer

• In 2014 the European Lung cancer award in Athens• he is Chevalier of French Legion d honneur

After a 5 years as CEO of Institute Claudius Regaud in Toulouse, he is now (2015) back in Paris as senior consultant in the drug development department (DITEP) at Institute GUSTAVE ROUSSY and Chief Medical Strategy Officer at Cancer campus Grand Paris.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Benoit BARTEAU is Senior Investment Manager in the Life Sciences Depart-ment of Bpifrance Investissement. Since 2014, he has been involved in around 10 investment deals. Prior to Bpifrance, Benoit has gained over 7 years of biotech experience in various positions. In 2007, as a scientist, he joined the start-up In-Cell-Art where he co-discovered a vaccine candidate, developed an antibody production service and was co-author of 9 scientific articles.

In 2010, as scientific and business development Manager of In-cell-Art, he was involved in the pre-clinical development of a vaccine candidate and developed antibody sales, contributing to the significant growth the company over the period. Benoit holds a Master Degree in Biotechnology Engineering from the University of Technology of Compiègne (UTC), a PhD in immunology from the University of Nantes and an executive Master in Finance from IAE Paris.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Benoit BARTEAUSenior Investmant Manager

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

After one year in the Innovation Task Force of the European Medicines Agency in London, Marion joined Bpifrance - the French Public Investment Bank - in 2011. She financed and followed more than 100 French startups in Life Sciences, IT and Healthcare.

In 2015, she joined Bpifrance Le Hub, a new activity within Bpifrance aiming at catalyzing partnerships and corporate investments between large corpora-tions, SMEs and startups.

Marion is particularly focused on sourcing relevant startups for selected cor-porate customers, and setting up the first interactions.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Marion CASSIAUManager, Bpifrance Le Hub

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

After one year in the Innovation Task Force of the European Medicines Agency in London, Marion joined Bpifrance - the French Public Investment Bank - in 2011. She financed and followed more than 100 French startups in Life Sciences, IT and Healthcare.

In 2015, she joined Bpifrance Le Hub, a new activity within Bpifrance aiming at catalyzing partnerships and corporate investments between large corpora-tions, SMEs and startups.

Marion is particularly focused on sourcing relevant startups for selected cor-porate customers, and setting up the first interactions.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Nathalie CHAPUT

PU-PH - Laboratory of Immuno-Onclogy (L.I.O) & Cell therapy unit Gustave Roussy Institute & Paris-Sud University

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Marie-Pierre Chevalier is the Strategic Alliance Director at Pfizer in France, where she is responsible for establishing new research collaborations and exploring licensing and other development opportunities across all therapeu-tic areas strategic for Pfizer.

After having worked in the hospital in the field of neonatology and pediatrics, she started her career in pharmaceutical industry with extensive experience in Oncology field in Clinical Research, Medical Affairs and Business Deve-lopment positions. She joined Pfizer in 2003, supporting the oncology new product portfolio and then took increasing responsibilities as Medical Com-munication Director for all portfolio products. In 2009, she was appointed Strategic Alliances Director for France.

She graduated as Doctor in Medicine and held a Master degree in Manage-ment at the Pierre & Marie Curie University, Paris.

She is currently member of the Strategic Committee of InnoBio fund (Public-Private VC funds in Health and life Science), member of the Scientific Advisory Board of Inserm Transfert Initiative (Seed funds), and member of the Selection Committee of iPEPS (incubator of the Brain Institute – ICM at Paris Pitié-Sal-pétrière Hospital).

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Marie-Pierre CHEVALIERMD - Strategic Alliances Director - Pfizer

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


Christian Deleuze is currently the President of Sanofi Genzyme France and Genzyme Polyclonals, part of the Sanofi Group. He joined the company in 2010 and leads the company’s strategic planning in line with the global Sanofi Genzyme mission, ensuring patients are provided with treatments, driven by cutting-edge science and a commitment to treating unmet medical needs in Rare Diseases, Multiple Sclerosis and recently Oncology and Immunology. He obtained his medical degree from, Lariboisière Saint-Louis in Paris and graduated from the ESSEC Business & Management School In the early 90’s. He began his professional pharmaceutical career at Bayer Pharma, and from there went on to hold different positions at Searl, Pharmacia and Pfizer where he was Marketing Director and responsible for the launch of Celebrex, in charge of strategy and tactics for branding and global positioning. In 2003 he created the French subsidiary of Sankyo Pharma, which became Daiichi Sankyo France. In his role as President and founder, from 2003 to 2010, he positioned France as the European leader for the Japanese group, with 500 employees. Today Christian is also President of the Rare Disease Committee at the LEEM (the French pharma syndicate), where he sits on the board and is a member of both the Administration Committee and the Biotechnology Committee. The LEEM Rare disease group unites the rare disease community; pharmaceutical companies, association representatives and health institutions dedicated to the orphan disease cause. Sanofi Genzyme exists in France since 1994 and counts over 400 employees in total. The headquarters are situated in Saint Germain en Laye (78), with teams throughout the French regions including activities in French overseas territories and in Lyon at the Polyclonal bioproducion site. The plant is in the Gerland district in Lyon, the world renowned biotech cluster. The site produces polyclonal antibodies preventing organ rejection in transplanted patients. This product is exclusively produced by Sanofi Genzyme in Lyon and is available in 68 countries worldwide.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Christian DELEUZEPrésident de Sanofi (Genzyme)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Gilles FAVREDirecteur du Cancéropôle Grand Sud-Ouest

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Pierre-Claude FUMOLEAUDirecteur Général AbbVie France

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Chahra Louafi is Senior Investment Director and Head of the Biotherapies and Rare Diseases Fund of Bpifrance (formerly CDC Entreprises). Before joining CDC Entreprises in 2001, Chahra Louafi was in charge of project development and company creation for a private incubator that specialised in biotechnolo-gies. She is Chairman of the Supervisory Board of Inserm Transfert Initiative and member of the Supervisory Board of Cap Decisif Management.

She has invested in and is on the board of DBV Technologies – which went public on Euronext Paris and on Nasdaq, Eyevensys, Sensorion – which went public on Alternext, MedDay Pharmaceuticals, Pixium Vision – which went public on Euronext Paris, Lysogene, Annapurna Therapeutics - which was successfully sold to Avalanche Biotechnologies, BrainEver, Enyo Pharma, Gecko Biomedical, GMP-Orphan, Sparingvision and Therachon.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Rafaèle Tordjman, MD, PhD, worked as a research scientist at the Institut National de la Recherche Médicale (INSERM) in Cochin Hospital, Paris. Before joining INSERM, she was a medical doctor specializing in clinical haematology and internal medicine. She obtained her PhD, with high honours, in haema-topoiesis and angiogenesis from the University Paris VII followed by a post doctoral fellowship in immunology.

Rafaèle obtained her medical degree and her specialisation in Haematolo-gy and Internal Medicine as a five-year fellow in Paris University Hospitals. She also participated in the “Young Manager Program” at INSEAD (France, in 2002). She has invested in and is on the board of Ascendis [ASC], DBV technologies [DVBT] – which went public on Euronext Paris and on Nasdaq, Nucana Biomed, MedDay, ObsEva, Lysogene and Enyo Pharma.

She was also on the board of Corevalve, Endoart before it was successfully sold to Allergan Inc, of Preglem before the latter was successfully sold to Gedeon Richter, HBI Ltd before being acquired by Meda and of Flexion Thera-peutics – which went public on Nasdaq.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Rafaèle TORDJMAN

Présidente de WITH,Women Innovating Together In Healtcare

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Cahra LOUAFIDirectrice d’investissements, Bpifrance

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Annick Schwebig joined Actelion in 2000. Her primary task, as General Mana-ger of Actelion Pharmaceuticals France, was to set up and develop the French affiliate. Prior to that, Annick Schwebig held various positions of increasing importance within Bristol-Myers Squibb where she was Vice-President for Research & Development in Europe from 1993 to 2000.

Her other responsibilities include:• Vice-President of the non-governmental organization “Equilibres & Popu-

lations”• Member of the Paris Ile de France Chamber of Commerce and Industry• Member of experts committee « funds large venture » within BPI France (a

Public Investment Bank)• Cellectis Administrator• Board of Trustees Member of the ESSEC Business School• Vice-President of the Inserm strategic council

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Annick SCHWEBIG

Présidente d’Actelion France (2000-2015)et du Comité Biotechnologies du Leem (2000-2016) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Les sociétésde biotechnologies

Biotech companies. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Activity

Affilogic is a privately-owned biotechnology company (SME) incorporated in Nantes early 2010. Affilogic is engaged in design of ideal targeted molecules from functional affinity proteins, Nanofitins. Each Nanofitin module provides a unique function to the assembled molecule through its specific interaction with an element of the body.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Expertise and Technological Skills

Affilogic has developed modules (i) inhibiting different cytokines (ii) controlling the residence time in the circulation, (iii) targeting specific receptors (iv) penetrating into tumor cells (iv) generating toxicity in the cells thus invaded (v) recruiting immune system (vi) crossing membranes…Each module is 20 times smaller than an antibody and hyperstable: resistant to the tumor environment, non-injectable adminis-tration (oral, topical, inhalation). Nanofitins are combined with each other or with third party by simple, rapid and proven methods.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Ongoing Collaboration and References

Affilogic has implemented a mixed business model: custom discovery and development of Nanofitins with partners, and internal exploration programmes for subsequent licensing. The company has entered into several development and license agreements with pharmaceutical stakeholders such as Sanofi, Takeda, and other major undisclosed companies to fully harness the potential of Nanofitins as therapeutic modalities.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Sought Opportunities

The overall strategy of Affilogic is to treat cancer via multiple pathways thanks to multi-functional Nanofitin-based targeted drugs. Two partnering schemes are possible (i) Affilogic can partner with pharmaceutical companies on existing Nanofitin modules cur-rently developed in immuno-oncology that are not encumbered by any exclusivity rights given to a current partner and / or (ii) we can generate new Nanofitins since we also have a platform-based business model.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Activity

Altevax is developing and will bring to market a melanin-based vaccine technology that is an effective treatment for cancer and infectious diseases. This technology, which has been proven in pre-clinical trials and has a patent pending, boosts the immune response to specific antigens with cytotoxic lymphocytes (Cytotoxic T-lymphocytes, CTLs or CD8+ lymphocytes), the body’s most powerful defendants.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


The Altevax technology, developed by Prof. Antoine Carpentier at AP-HP, is based on nanoparticles of melanin (an adjuvant) embed-ding an antigen. Vaccines using such formulations have shown a significantly higher efficacy in triggering cellular immunity than that obtained with currently available adjuvants. Altevax has an exclusive, worldwide licence from AP-HP to develop and market this technology. Prof. Carpentier is the Scientific Director of Altevax.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


Altevax is working in close collaboration with Prof. Carpentier’s lab at AP-HP, as well as Prof. Eric Tartour’s lab (Immunology, HEGP), and Prof. Laurence Motte’s lab (Physics and biomaterials, Université Paris XIII).Publication: Carpentier AF, Geinguenaud F, Tran T, Sejalon F, Martin A, Motte L, Tartour E, Banissi C. Synthetic melanin bound to subunit vaccine antigens significantly enhances CD8+ T-cell responses. PLoS One July 17, 2017https://doi.org/10.1371/journal.pone.0181403

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


The Altevax technology has been proven to treat tumours in mice. The next development step is its pre-approval by health autho-rities in targeted markets, followed by clinical trials in humans. Altevax intends to build co-development partnerships with pharma companies with expertise and distribution capabilities in immuno-oncology to undertake this process for specific antigens, and to then market the finished vaccine product.

Name of the company: AFFILOGICName of the manager: Olivier KITTENTelephone: +33 (0)2 40 35 49 18e-mail: [email protected]: Nantes - FRANCE

Name of the company: ALTEVAX SASName of the manager: Victor VADANEAUXTelephone: +44 7768 867 232e-mail: [email protected] Location: Paris - FRANCE/London - UK


. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Activity

Founded in 2007, B Cell Design is focused on drug discovery. A spin-off of a CNRS academic laboratory from Limoges University, B Cell Design develops an original concept of mucosal immunotherapy based on a new class of monoclonal antibody. Two molecules are currently in development, a vaccine candidate against HIV and a drug candidate in immunotherapy for the colorectal cancer.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


The innovation is based on a platform of transgenic mice, able to generate numerous of highly specific monoclonal antibodies, directly humanized and from a specific isotype. With our solid knowledge on immune mechanisms involved in all the mucosal bar-riers of our body, B Cell Design develops immunotherapies to cure intestinal mucosa targeted by colorectal cancer or prophylactic vaccine to protect genital mucosa, the first gate of entrance of HIV virus.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


B Cell Design has established collaborations with academics (CNRS, INSERM, University of Limoges, University of Lyon, Saint-Etienne, and University of Strasbourg) and pharma companies (including SANOFI). Several patents as well as international articles have been published following collaborative studies.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


With the development of the first monoclonal anti-colorectal cancer IgA, B CELL DESIGN wish for validation of the therapeutic concept of the use of IgA in mucosal targeting therapy. At the completion of the regulatory preclinical phase, we are seeking for a partnership with a pharmaceutical company, with reference expertise for the pursuit of clinical trials in humans and for reaching the market.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Activity

CarThera developed the SonoCloud®, an intracranial ultrasound implant that temporarily opens the blood-brain barrier (BBB). By increasing the permeability of the cerebral blood vessels using low intensity pulsed ultrasound, the concentration of therapeutic molecules that reach the brain can be increased by up to seven times and improve dramatically the outcome of chemotherapy and immunotherapy procedures in the treatment of brain diseases.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


CarThera has established a multidisciplinary organization with expert engineers for the successful development of breakthrough ultrasound-based medical devices, and lead scientists and physicians for the successful completion of its preclinical and clinical trials for treating brain disorders. The company has a seasoned management team with international scope and expertise in MedTech and BioTech. The intellectual property is covered with a rich patent portfolio.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


CarThera developed collaborations with renowned institutes: LabTau (INSERM lab specialized in therapeutic ultrasound), UPMC and AP-HP for clinical developments, ICM and CEA for preclinical trials, IM2A for exploratory studies in Alzheimer. Moreover, neurosurgeon, neurologists and neurooncologistsn from the most prestigious French and American hospitals (MD Anderson, Nor-thwestern Hospital and UCSF) accompany the team at CarThera and share their knowledge and experience.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


CarThera’s hypothesis is that BBB opening with SonoCloud® will increase brain penetration of immunotherapies and will help at boosting immunity in the brain. SonoCloud® device may notably be used with investigational or commercialized immunotherapies with the goal to control brain disease with the same magnitude as for systemic disease.CarThera is thus interested in entering collaborations with pharmaceutical companies or biotech interested in evaluating the combined use of their agents with its SonoCloud® device.

Name of the company: B CELL DESIGNName of the manager: Armelle CUVILLIERTelephone: +33 (0)5 55 12 30 21e-mail: [email protected]: 98, rue Charles Legendre, 87000 Limoges - FRANCE

Name of the company: CARTHERAName of the manager: Frédéric SOTTILINITelephone: +33 (0)6 76 10 33 96e-mail: [email protected]: ICM


. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Activity

ElsaLys Biotech is a biotech company that designs and develops “best-in-disease” therapeutic antibodies targeting tumors and their immune and/or vascular microenvironment. By restoring the ability of immune cells to recognize and kill tumors (ICI) or by blocking the mechanisms that promote their growth (targeted mAbs), ElsaLys Biotech widens the range of combinations in onco-logy and in ophthalmology with strong potential therapeutic targets.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


To drive its developments, the company relies on a robust academic international network, an internal R&D platform that covers from targets sourcing to clinical development of drug candidates and a team of experts with solid experience in immuno-oncology and antibodies development. Today, ElsaLys Biotech is advancing four R&D proprietary development programs in oncology and in ophthalmology.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


The different programs are conducted in collaboration with academic lab in Germany (M. Seiffert, V. Umansky DKZF), in France (Pr Mauvieux, Hautepierre Hospital, Strasbourg; C Caux, Centre Leon Bérard; S.Germain, Collège de france; C.Arndt, CHU Reims/Institut Jean Godinot), in the US (R.Birge, State University of New Jersey), in the UK (F. Mussai, University of Birmingham) and in Spain (D. Benitez-Ribas, Hospital Clínic de Barcelona).

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


The number of cancers is expected to increase dramatically over the next 20 years. Even though constant progress, some current treatments have limited efficacy, alone or in combination. Developing new, more specific and less toxic treatments could help to address these medical gaps, to overcome the resistance, to increase the therapeutic options for combination therapies and improve patients’ outcome and quality of life.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Activity

ElyssaMed® is developing an active immunotherapy against cancer, mainly non-small-cell lung cancer (NSCLC), but also neu-roendocrine tumors (NET) and medullary thyroid carcinomas (MTC), which are classified as orphan diseases. This immunotherapy is based on five antigenic peptides derived from a tumor antigen, the preprocalcitonin (ppCT) antigen, and an adjuvant. It differs from all other concurrent immunotherapy approaches by its mode of action, which permit to overcome tumor escape from the immune system and thus its use in multi-resistant patients.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


This cancer immunotherapy is based on the discovery of a new tumor antigen, the ppCT antigen. The team has demonstrated that ppCT is expressed in several human lung tumors and is able of inducing a specific antitumor immune response in many cancer patients. ppCT is characterized by the inclusion of a T-cell epitope processed by a novel mechanism that permits CD8 T-cell immunity to destroy immune-escaped tumors. The ultimate goal is to combine this immunotherapy with an immune checkpoint inhibitor (anti-PD-1) and with mutated peptides (neoepitopes) identified in each patient’s tumor for a more personalized thera-peutic cancer vaccine.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


• Prof. Benjamin BESSE, Gustave Roussy; Prof. Pierre COULIE, ULB Bruxelles, Prof. PEDRO ROMERO, Ludwig Institutes Lau-sanne, Prof. Matthieu Montes (CNAM).

• El Hage F, Stroobant V, Vergnon I, Baurain F, Echchakir H, Lazar V, Chouaib S, Coulie PG and Mami-Chouaib F. Identification of a cytotoxic T lymphocyte-defined human lung carcinoma epitope processed by a proteasomeindependent pathway. Proc Natl Acad Sci. USA. 2008. 105: 10119-10124.

• Durgeau A, El Hage F, Vergnon I, Besse B, J-C Soria, Van Hall T and Mami-Chouaib F. Different expression levels of the TAP peptide transporter lead to recognition of different antigenic peptides by tumor-specific CTL. J Immunol. 2011. 87(11):5532-9.

• Doorduijn EM, Sluijter M, Querido BJ, Oliveira CC, Achour A, Ossendorp F, van der Burg SH, van Hall T. TAPindependent self-peptides enhance T cell recognition of immune-escaped tumors. J Clin Invest. 2016 126(2):784-94.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


Today we are looking for a financing support for our Phase 1b clinical trial. It could be a pharmaceutical company or a financial investor.

Name of the company: ElsaLys BIOTECHName of the manager: Christine GUILLENTelephone: +33 (0)4 37 28 73 00e-mail: [email protected]: Lyon - FRANCE

Name of the company: ELYSSAMED SASName of the manager: Fathia MAMITelephone: +33 (0)6 40 40 11 48e-mail: [email protected]: Paris - FRANCE


. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Activity

GamaMabs Pharma is a clinical-stage French immuno-oncology biotechnology company developing breakthrough antibody-based therapeutics. Gamamabs’ first-in-class proprietary therapeutic monoclonal antibodies have unique mechanism of action of killing tumor cells though the activation of immune cells. Its lead project is the first-in-class monoclonal antibody GM102 which targets AMHR2, currently tested in gynecological cancer patients.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


Gamamabs has developed a unique know-how on both the AMHRII target and on immuno-enhancing antibodies (EMAbling® technology). AMHRII is an untapped target that is re-expressed in carcinogenesis in a wide range of solid tumors. EMAbling® technology enables antibodies to activate tumor-environment immune cells (macrophages and NK cells) and restore their ability to kill tumor cells.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


Gamamabs has developed a unique network of collaborations in Europe and in in the US with leading research centers and renown opinion leaders in oncology clinical research, such as Inserm, Institut Curie, Institut Gustave Roussy, IUC Toulouse, Mayo Clinic (US) and Mass General Hospital (US). GamaMabs has an industrial collaboration with LFB (France) on Emabling® technology.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


Gamamabs is searching for development collaborations with leading oncology Pharma on its GM102 drug, in particular in view of trying combinations trials combining GM102 with check point inhibitors.

Name of the company: GAMAMABS PHARMAName of the manager: Stéphane DEGOVETelephone: +33 (0)1 70 96 00 67e-mail: [email protected]: Toulouse & Paris - FRANCE

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Activity

GlioCure is a biotech company dedicated to the treatment of glioblastoma (GBM), the most frequent and aggressive brain tumor with a fatal outcome. GlioCure is currently focusing on the development of GC01, a first-in-class anti-mitotic peptide with a spe-cific anti-glioblastoma activity, derived from its targeting and penetrating glioblastoma and brain-tumor-initiating cells proprietary platform (GlioVector).

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


GlioCure’s management team is composed of LM Bachelot (CEO), a serial biotech entrepreneur, and C Lépinoux-Chambaud (COO, Head of R&D), a neurosciences researcher, co-discoverer of GC01. Its SMAB gathers Dr. J Eyer, DR Inserm, main discoverer of GC01, Prof. ME Halatsch, Vice-Chair of the Neurosurgery Department at Ulm University, Dr. JP Bizarri, a world renowned expert in clinical oncology, and Dr. J Richard, Senior Vice-President Peptides Development at Ipsen Group.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


GC01 has been reviewed, selected and supported by the international board of MATWINGlioCure is one of the four partners (with UMR Inserm 1066-CNRS 6021 Angers, ADDB Louvain Drug Research Institute and Faculty of Pharmacy Laval Uni. Québec) of the EuroNanoMed III Gliogel project that intends to develop a gel-based device composed of lipid nanocapsules vectorized by GlioVector for the controlled and sustained release of chemotherapeutic drugs within the resec-tion cavity of glioblastoma tumors.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


GlioCure is looking for an industrial partner that can bring significant capacities and expertise regarding the manufacturing and regulatory submissions of anticancer drugs, to boost the preclinical development of GC01 and support the launch of a first-in-human study within three years.

Name of the company: GLIOCUREName of the manager: Claire LÉPINOUX-CHAMBAUDTelephone: +33 (0)6 72 82 06 42e-mail: [email protected]: Institut de Biologie en Santé, CHU, rue Larrey, 49933 Angers - FRANCE


. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Activity

HalioDx SAS is an immuno-oncology diagnostic company that designs and develops a unique range of immune scoring tests. By precisely measuring the immune reaction in and around the tumor, HalioDx tests allow the clinician to determine the degree of severity of the patient’s disease and predict the response to treatment, regardless of the cancer stage or the molecular class.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


HalioDx was founded in 2014 as a spin-off of Qiagen-Marseille by a team of seasoned managers with anextensive track records in the cancer diagnostic field, and a pioneer in integrative immunology andoncology, Dr. Jérôme Galon. HalioDx benefits of worldwide licences on a broad portfolio of IP rights onimmuno-oncology biomarkers. With an experienced team of more than 120 employees and US and CEregulatory compliant facilities, HalioDx develops, manufactures, delivers and markets IVD products andservices in immuno-oncology.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


HalioDx collaborates with an increasing number of renowned international clinical groups like the Mayo Clinic in US, the French intergroup PRODIGE, Gustave Roussy Institute, to conduct clinical utility studies and ensure rigorous performance validation of its assays in a large number of cancer indications. HalioDx also collaborates with biopharmaceutical companies such as Lytix, Kite or Nanobiotix to support their biomarker strategy along with their clinical development programmes.Some of those collaborations are described in more details in our Press release section available on our website.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


The objective of the company is to:• Develop Immunoscore® Colon as a standard in the management of stage II and III colon cancer• Expand Immunoscore® and related assays to other cancer types and respond to unmet medical needs• Empowering Pharma Companies with a comprehensive biomarker portfolio and technologies in order to support them in

their companion diagnostics development.

Name of the company: HALIODXName of the manager: Vincent FERTTelephone: +33 (0)4 91 29 30 90e-mail: [email protected]: Luminy Biotech Entreprises, 163 avenue de Luminy, 13288 Marseille CEDEX 9 - FRANCE

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Activity

H-IMMUNE is an emerging player in the field of immune-oncology (I/O). The company is deploying a proprietary highly-potentate discovery engine against novel first in class to build-up an early stage drug program pipeline to be solely developed or in par-tnership.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


The key element of H-Immune’s core expertise is the leveraging of its proprietary In Vitro Immunization (IVI) platform, which has a unique ability to generate a series of fully human antibodies against the entire epitope mapping of any therapeutic target by taking advantage of the affinity maturation processes performed directly in situ by B lymphocytes.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


Academic Partners: CEA Saclay (Dr M. Leonetti, PhD), Gustave Roussy (Dr P. Busson, MD PhD)Industrial Partners: Laboratoires Pierres Fabre, Northern Biologics

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


• IVI-based antibody campaign partnership opportunities• Co-development of early stage drug program against emerging first in class target in the I/O space.

Name of the company: H-IMMUNEName of the manager: Luc BOBLETTelephone: +33 (0)6 49 17 45 11e-mail: [email protected] Location: Paris - FRANCE


. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Activity

ImCheck is developing two first-in-class immunomodulator antibodies and is advancing several discovery programs on undis-closed targets, which play a defined immune-modulating role in both innate and adaptive immunity. ImCheck is implementing new translational R&D approaches combining predictive biomarkers development, experimental models based on freshly isolated human tumor samples and long established partnerships with a network of world class scientists.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


• Large panel of «checkpoint inhibitors» characterized by Olive’s team which represent an opportunity to by-pass • resistances to anti-CTLA-4 and anti-PD-1 antibodies.• Functional modulation of Tumor Infiltrating Lymphocytes isolated from fresh tumor samples• CD4, CD8 and γδ-T cells immune research• Preclinical and early clinical development expertise

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


Academic collaboration with renowned institutions in the field of tumor immunology

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


• Imcheck may enter into partnering discussion for its asset(s) in order to accelerate the development of the company:• 2 assets in preclinical development (INDs in 2019) for IO and infections• 1-2 candidates ready for preclinical development (autoimmunity, GVHD)• Drug discovery pipeline (5 target validation program)

Name of the company: IMCHECK THERAPEUTICSName of the manager: Pierre D’EPENOUXTelephone: +33 (0)6 38 13 12 36e-mail: [email protected]: 249 Bd de Sainte-Marguerite, 13009 Marseille - FRANCE

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Activity

Inovactis has developed a genetically modified S. cerevisiae (yeast) immunotherapy to safely induce a targeted immune response against any cancer type. Through a patented technique, Inovactis engineers the yeast to produce specific tumor neoantigens and antibodies that modify in vivo the patient immune system. At present, Inovactis yeast platform technology is aiming at fighting metastatic melanoma and the colorectal cancer MSS in a personalized way. The melanoma treatment market is expected to reach €5 billion by 2023, while the colorectal cancer will reach €11 billion by 2025.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


Inovactis technology relies on synthetic biology to create personalized yeast immunotherapy, and Inovactis co-founders are ex-perts in the synthetic biology field.Dr Jean-Jacques Garaud is Inovactis strategic advisor. He was previously director of Roche early development.Carole Pottier Garaud is Inovactis pre-clinical project development director.Pr Bruno Colombo, an expert in dendritic cells immunotherapy, is a scientific board member of Inovactis.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


Inovactis collaborates with the Curie Institute (Paris V) for its cancer in vivo trials.Inovactis has a partnership with Traaser, a genomic data company located at Genopole, for the patient neoantigens discovery.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


Inovactis is looking for co-development opportunities of its personalized immunotherapy with the pharmaceutical industry or major drug biotech companies.

Name of the company: INOVACTISName of the manager: Clément DE OBALDIATelephone: +33 (0)6 61 99 78 02e-mail: [email protected]: Evry - FRANCE


. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Activity

MEDSENIC develops a medication for autoimmune diseases, based on a CNRS patent family, under an exclusive worldwide licence agreement. The drug- arsenic trioxide- has already an excellent record in terms of pharmacovigilance and safety in the field of cancer, is is being repositioned by MEDSENIC for chronic Graft-versus-host disease, systemic lupus erythematosus and systemic sclerosis. The development stage is now Phase II clinical studies at the national and international levels including positive preclinical and clinical Proofs of Concept, allowing further trials to firmly establish safety and efficacy of the treatment regimens.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


MEDSENIC has three main fields of activity with corresponding skills and technical abilities:• MEDSENIC now masters the GMP manufacturing and analysis techniques for aqueous preparations of its arsenic trioxide

(Arscimed® ) for intravenous injections,• MEDSENIC has set up the preclinical experiments on animal models to evaluate precisely evaluate and discover the mode

of action of arsenic salts at the cellular and molecular levels (specific immunoregulation and not immunosuppression),• MEDSENIC controls its Phase II human clinical trials from protocol setup to validated statistical significance of data.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


Collaborations have been set up:• with public and private laboratories expert in animal models, especially using mice, either genetically modified or pharma-

cologically treated,• with CMOs (namely Pierre Fabre) for complex sterile manufacturing of its cytotoxic own production of injectable arsenic

trioxide, named Arscimed®,• with CROs (for GvHDc: Fovea/PopsiCube) for the follow up and monitoring of its Phase 2 studies,• with consulting agencies specialized in reglementary (Voisin Consulting) and intellectual Properties affairs (Plasseraud

Consulting).

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


Industrial or capital venture partnership for clinical trials extensions and Market Access, in various medical applications in the autoimmunity field.

Name of the company: MEDSENIC SASName of the manager: François RIEGERTelephone: +33 (0)6 71 73 31 59e-mail: [email protected]: Strasbourg - FRANCE

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Activity

Nanobiotix is a late clinical-stage nanomedicine company pioneering novel approaches for the treatment of cancer. The Compa-ny’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to providing a new, more efficient treatment for cancer patients.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, etc., via multiple routes of administration. NBTXR3 is being evaluated in: soft tissue sarcoma (STS), head and neck cancers, prostate cancer, and liver cancers (primary and metastases). Additionally, head and neck cancer and rectal cancer trials led by Nanobiotix’s Taiwanese partner, PharmaEngine, are underway in the Asia Pacific region. The Company has filed in August 2016 for market approval (CE Marking) in Europe for its lead product NBTXR3.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


Not available at this time but in progress.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


Funding and collaboration with big pharma.

Name of the company: NANOBIOTIX SAName of the manager: Laurent LEVYTelephone: +33 (0)1 75 44 72 33e-mail: mail: [email protected]: 60 rue de Wattignies, 75012 Paris - FRANCE


. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Activity

Novadiscovery is a professional services firm specialized in in silico clinical trials founded in Lyon, France in 2010. The company supports its biotech and pharma partners R&D programs through the upstream prediction of drug candidate efficacy by computer simulation long before human trials to improve R&D output.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


The company combines experts in biology, mathematical modeling, computer science, clinical pharmacology and medicine.The company’s WISE technology (“Whitebox In Silico Engine”) combines a communitydriven “knowledge engine” to curate and organize biomedical knowledge (GitHealth) with modeling & simulation “action engine” industrializing the company’s standard operating procedures (“SimWork”).

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


The company has already successfully served big pharmas and biotechs (Bristol-Myers Squibb in immuno-oncology, Sanofi…). We currently work with a handful of biotechs in various therapeutic areas. We are also part of an RHU project (PIONeeR) which is expected to launch by year-end in collaboration with academic centers in Marseille and AstraZeneca in immunooncology.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


The company intends to increase its visibility in the ecosystem via RIB 2018 with a view to expand its business development portfolio as well as engage with potential investors to support its scale-up phase.

Name of the company: NOVADISCOVERYName of the manager: François-Henri BOISSELTelephone: +33 (0)6 75 48 31 81e-mail: [email protected]: Lyon - FRANCE

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Activity

OREGON THERAPEUTICS is a company developing XCE853, a “First in class” & “Best in class” drug candidate with an innovative and unique mechanism of action: Inhibition of Protein Disulfide Isomerase (PDI). OREGON THERAPEUTICS 1st objective is to bring the drug candidate XCE853 into clinical trial (Phase 1) for the treatment of human cancer within 2 years. Based on the scientific rationale, priority indication is advanced PANCREAS cancer.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


A team of key managers with strong oncology backgrounds is working in cooperation with international centers of excellence in the field of oncology. This team of highly experienced key managers includes former pharma and biotech executives with success-ful track records. The breadth of experience includes R&D project management, operations and start-up experience.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


• Professor Nouri Neamati, University of Michigan, USA• Dr Michèle Sabbah et Nathalie Ferrand – Hôpital Saint Antoine Paris, France• Dr Catherine Brenner& Dr Claudine Deloménie, Université Paris-Sud, France• National Cancer Institute (NCI) Bethesda, USA• Dr Annemilaï Raballand & Dr Armand de Gramont Groupe AFR, France• Dr Anne Chauchereau & Dr Michele Mondini - Gustave Roussy, Villejuif, France• Professor Paul Foster, University of Birmingham, England• Professor Eric Raymond, Hôpital Saint Joseph, Université Paris Diderot, Paris, France

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


The company’s short term aim is to create value by performing the Proof of Concept in human of this new drug to treat cancers. After completion of the first in man study, the phase II will allow to demonstrate the clinical benefit of XCE853. The “First in Class” positioning: Unique mechanism of action on a validated new target, with no direct competitors. Higher antitumor activity against cancers where the medical need is very high (i.e.: Pancreas, Ovarian, Head & Neck, Liver Cancers) - XCE853 is specifically active on drug-resistant tumor cells Combinations of XCE853 with chemotherapy or radiotherapy increase the antitumor benefit. Biomar-kers of XCE853 early antitumor activity have been validated.

Name of the company: OREGONTHERAPEUTICS SASName of the manager: DR MH PITTYTelephone: +33 (0)6 01 03 43 43e-mail: [email protected]: AGORANOV, 96bis Bd Raspail, 75006 Paris - France


. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Activity

Stimunity develops new biopharmaceuticals based on Virus-Like Particles (VLP) to treat patients that do not respond to conventio-nal immunotherapies in oncology (anti-checkpoint therapy).

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


Stimunity’s biopharmaceuticals are based on the VLP-cGAMP platform technology which activates the innate immune system via the STING pathway and induces T-cell response against tumor cells.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


• R&D collaboration with Institut Curie• Laureate of the i-lab 2017 national competition• Laureate of the Scientipôle Initiative in biotechnology• 2016 Biovision Catalyzer Special Award

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


• Seed investment of 2M€• Co-development partnership

Name of the company: STIMUNITYName of the manager: Sylvain CARLIOZTelephone: +33 (0)6 10 58 57 65e-mail: [email protected]: 24 rue du Faubourg Saint-Jacques, 75014 Paris, FRANCE

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Activity

Theraclion is a pioneer in the therapeutic use of ultrasound (HIFU). Theraclion develops, manufactures and markets the Echo-pulse® medical device for the non-invasive, outpatient treatment of breast fibroadenomas and benign thyroid nodules. Its clinical research activity is starting now in Cancer as FDA authorized first combined trial to treat stage 4 Breast cancer, combining pem-broluzimab and HIFU.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


Theraclion is currently the only company in the world offering a completely non-invasive treatment for breast fibroadenomas and benign thyroid nodules. It relies on ultrasound-guided high-intensity focused ultrasound for the thermo-ablation of tumor tissues.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


Theraclion is the first “Forfait Innovation”-approved to evaluate the medical-economic benefits of HIFU in a randomized control trial vs. surgical excision of benign breast tumors.Theraclion is also involved with University of Virginia for the first-in-the-world test of a combined treatment of stage 4 metastatic breast cancer with HIFU and anti-PD1 checkpoint inhibitor prembrolizumab.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


Pioneer in therapeutic ultrasound, Theraclion could accelerate its oncology developments through an industry or financial partner-ship to strengthen its position in the highly promising immuno-oncology area.

Name of the company: THERACLIONName of the manager: David CAUMARTINTelephone: +33 (0)6 55 48 90 70e-mail:[email protected]: 102 rue Etienne Dolet, 92240 Malakoff - France


. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Activity

THERAVECTYS, a privately-owned biotech company, translates 20+ years of research on lentiviral vectors into actionable innova-tion and delivers remarkably safe and highly efficient T-cell vaccines as a response to critical unmet medical needs. Leveraging its versatile technology, TheraVectys develops immunotherapies in a large number of applications in infectious diseases, virally-induced cancers and cancers.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


Founded by pioneer inventor Dr. Pierre Charneau, as a spin-off of the Pasteur Institute, TheraVectys’ technological core skills lie in lentiviral vectors vaccines design, optimization and development. Today TheraVectys also benefits from a Joint-Lab with the Pasteur Institute, and therefore from the extensive experience of the technology founder in vaccine development, lentiviral vectors, and more broadly in infectiology.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


TheraVectys benefits from an on-campus R&D laboratory partnership (Joint Lab) with the Pasteur Institute, that ensures organic collaboration and synergies while it also continuously widens and enriches TheraVectys’ patent portfolio. Additionally, several co-development collaborations and sub-licensing deals are currently under advanced negotiation.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


TheraVectys is actively seeking partners for: (1) Co-development & collaboration for POC-validated vaccine candidates in infec-tious diseases; (2) Out-Licensing for POC-validated vaccine candidates for veterinary applications or out-licensing of broader veterinary vaccines rights; (3) Early Collaboration for our oncology developments in particular on tumor antigens discovery (neoan-tigens or pan-tumoral approaches).

Name of the company: THERAVECTYSName of the manager: Divya BABINTelephone: +1 617 866 7075e-mail: [email protected]: Paris - FRANCE/Cambridge - USA

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Activity

Vaxeal develops advanced immunotherapies based on long synthetic peptides in combination with immunomodulatory drugs to meet the growing need for improved anti-cancer treatments. Our unique and innovative scientific research, and our improved understanding of immunological mechanisms, are at the heart of Vaxeal’s mission to deliver cutting-edge therapies. Vaxeal’s initial programs have reached the pre-clinical stage, and will enter into clinical trials in 2018..

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


Vaxeal’s innovative technology platforms and core expertise has allowed the management team to develop an optimal and inno-vative combined strategy for the design of cancer immunotherapies enabling to overcome both efficacy, safety, and immunosup-pression issues encounter with current cancer immunotherapy approaches. This strategy is based on the synergistic combination of advanced therapeutic cancer vaccines with low doses of immune-checkpoint blockade therapies.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


Public-Private partnership is at the heart of Vaxeal’s product development strategy. Vaxeal has established strategic partnerships with leading European research institutions in healthcare, notably the with the life sciences department of the CEA. In collaboration with our partners, Vaxeal has also already obtained two grants for the development of its products. Vaxeal is also a member of two leading industrial bodies: European Biopharmaceutical Enterprises (EBE) and Vaccines Europe.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


By participating to RIB 2018, we expect to strengthen and accelerate our development by connecting to mentors, advisors and end-users. In addition, as we have successfully achieved our first milestones, consisting in the completion of ‘pre-clinical’ proof-of-concept stage on SVX-1, we are now looking to raise €7 million to complete our second major milestones, the Phase I/II of our most advanced cancer immunotherapy (SVX-1), and pre-clinical PoC of a second product (CBX-1).

Name of the company: VAXEALName of the manager: Dr Ahmed BouzidiTelephone: +33 (0)1 60 87 89 31Location: Evry - FRANCE


. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Les entreprisesdu medicament

Pharmaceuticalcompanies

IND

US

TR

IEL

S

Company name: ABBVIEHeadquarters: Chicago - USACompany size: 28 000 employeesAnnual sales 2015: 23 billion dollarsR&D Staff: 6500 employeesR&D investment: 4.4 billion dollarsHeadquarters: Cambridge, UK

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

COMPANY DESCRIPTION

AbbVie is a highly focused, research-driven bio-pharmaceutical company.

It takes a global leader to deliver patient-centered solutions around the world. We uniquely combine the assets and capabilities of an experienced pharmaceutical company with the flexibility and focus of a biotech to pursue the most meaningful opportunities for patients. The result is a biophar-maceutical company that offers new approaches to addressing today’s health issues — from life-threatening illness to chronic conditions.

We target specific difficult-tocure diseases where we can leverage our core research and develop-ment (R&D) expertise to advance science and create solutions that go beyond treating the ill-ness to have a positive impact on patients’ lives, as well as on economies, societies, and science itself. We look at problems holistically.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

HISTORY OF COMMITMENT

In neurology area, AbbVie has been committed for over 15 years to healthcare professionals and patients.

AbbVie priority is to contribute to improve knowledge, develop tools and make them avai-lable to healthcare professionals, to optimize patient care, improving their quality of life.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

PRODUCT PORTFOLIO IN THIS AREA

We launched a Parkinson’s disease (PD) treat-ment, levodopa-carbidopa intestinal gel, com-mitted to both treatment and scientific innovation

for Parkinson’s disease patients. PD is a progres-sive disorder of the brain that leads to shaking (tremors) and difficulty with walking, movement and coordination. A lack of dopamine in the brain results in abnormal nerve functioning, causing a loss in the ability to control body movements. PD is the second most common neurological disor-der worldwide after Alzheimer’s disease.

In 2016, AbbVie and Biogen offer an alternative approach, daclizumab, to treat multiple sclerosis (MS). AbbVie and Biogen co-promote daclizumab in the United States. Outside the United States, Biogen is responsible for commercialization.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

PROSPECTIVE IN THE AREA THEMATIC PRIORITIES

Our current innovative research focuses on com-pounds that have the potential to treat a variety of chronic disabling neurological conditions. We have several compounds in the early and advanced investigational phases for diseases such as Alzheimer’s disease, Parkinson’s disease, progressive parasupranuclear palsy, spinal cord injury and multiple sclerosis — all of which affect millions of people worldwide.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Company name: GLAXOSMITHKLINECompany size: 59 700 employeesNumber of countries: Present in 100 countriesAnnual sales: $21,3 billion EurosR&D investment: $5,9 billion Euros in five countriesHeadquarters: Cambridge, UK

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

COMPANY DESCRIPTION

AstraZeneca is a global, science-led biopharma-ceutical company that focuses on the discovery, development and commercialization of pres-cription medicines, primarily for the treatment of diseases in three therapy areas : oncology, cardiovascular & metabolic diseases & respira-tory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infec-tion. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.In France, AstraZeneca currently has 137 cli-nical development programs in oncology and concluded numerous partnerships in basic and translational research with academia. AstraZene-ca France participates in four major initiatives in precision medicine: SAFIR 02 (lung and breast cancers); AcSé ESMART (paediatric oncology) and MultiSarc (sarcoma programme part of the Médecine France génomique 2025 initiative), MOST (all tumours). The French subsidiary also partners in 2 French University-Hospital Research projects in lung cancer: PIONEER Project (PI: Prof. F. Barlesi, AMU/AP-HM) and LUMIERE project (PI: Prof L. Zitvogel, Gustave Roussy).

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


In Oncology, our vision is to respond to unmet medical need by redefining the cancer treatment paradigm. We are doing this through scientific innovation, accelerated clinical programmes and collaboration. We have a strong heritage – more than 40 years – in developing cancer drugs. We are one of only a handful of companies to span the entire lifecycle of a medicine from research and development to manufacturing and supply, and the global commercialisation of primary care

and speciality care medicines.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


ARIMIDEX (anastrozole) CALQUENCE (acalabrutinib), USA CASODEX (bicalutamide) FASLODEX (fulvestrant) IRESSA (gefitinib) IMFINZI (durvalumab), USALYNPARZA (olaparib)NOLVADEX (tamoxifen citrate)TAGRISSO (osimertinib)ZOLADEX (goserelin acetate implant)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

R&D Focus Portfolio and Prospective in this area

Our broad pipeline of next-generation medicines is focused on four main disease areas : breast, ova-rian, lung and haematological cancers, using four key scientific approaches: immunotherapy, tumour drivers and resistance mechanisms, DNA damage response, and antibody-drug conjugates:

• Tumour drivers and resistance mechanisms: Potent inhibition of genetic disease drivers is a clinically validated approach to shrink tumours and improve progression-free survival. Tumours, however, eventually develop resistance to these therapies. Our programmes seek to develop the-rapies that target resistance mechanisms and the mutations that cause cancer cells to proliferate.

• DNA damage response: Exploiting mechanisms that selectively damage tumour cell DNA is ano-ther clinically validated approach to shrink tu-mours and improve progression-free survival. Our programmes focus on identifying and exploiting vulnerabilities unique to tumour cells to kill the tu-mour cells while minimising toxicity to the patient.

• Immunotherapy: Our ambition is to be a scientific leader in immunotherapy, a promising therapeutic approach that harnesses the patient’s own im-mune system to help fight cancer. We are working to understand how cancer evades the immune system and to identify approaches that enhance the immune system’s ability to fight cancer.

• Antibody-drug conjugates: The use of antibody-drug conjugates (ADC) is a clinically validated, highly potent approach that selectively targets cancer cells. We seek to combine innovative antibody engineering capabilities with cytotoxic drug molecules to attack and kill the tumour while minimising toxicity to the patient.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

I have industrial development expertise with both large and small molecule cancer therapeutics, focusing on biomarker-driven early clinical deve-lopment. With over 20 years’ experience resear-ching DNA damage and repair, my current focus is on small molecules inhibiting key DNA replicative stress response pathways and on combinations with large molecule immuno-oncology check-point inhibitors. In addition to establishing clinical biomarkers of drug pharmacodynamics in Phase 1/2 programmes, I lead a team of Ph.D. level re-searchers implementing leading-edge biomarker analytical technologies for multiplexed transcrip-tomic and proteomic assessments. Implemen-tation of biomarker-led clinical window studies establishing relationships between peripheral and intratumoural drug response is a strategic point of emphasis.

Experience• Associate Director, Translational Science Onco-

logy, AstraZeneca IMED, UK | Sep 2014 – present• Senior Scientist, Translational Medicine Onco-

logy, MedImmune, USA | June 2011 – Sep 2014• Oncology Biomarker Analyst, N-of-One Thera-

peutics, USA | Nov 2010 – May 2011• Assistant Professor, Microbiology, Immunology

and Molecular Genetics, University of Kentucky, USA | Feb 2003 – Jan 2011

Education• BSc in Cellular and Molecular Biology, Univer-

sity of Toronto, Canada; • PhD in Molecular Genetics, University of North

Carolina at Chapel Hill, USA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Andrew J. PiercePh.D

These 4 platforms means 28 molecules in deve-lopment at different stages of clinical develop-ment and more than 30 programme assessing combination therapies, simultaneously attacking multiple mechanisms of tumour progression. Our strategy is supported by targeted business development to reinforce our therapy areas while supporting our long-term pipeline aspirations. We partner with others around the world, including academia, governments, industry and scientific organisations to access the best science to sti-mulate innovation and accelerate the delivery of new medicines to target unmet medical need. We currently have more than 600 collaborations around the world to access the best science to stimulate innovation and accelerate the delivery of new medicines to target unmet medical need.

In France, AstraZeneca signed with Innate Phar-ma a global co-development and commercialisa-tion collaboration in immuno-oncology in 2015 ; collaborated with Inserm teams since 2011, and participates in two projects in lung cancer evaluating the immuno-oncology approaches and laureates of University-Hospital Research in Health call for projects in the “Investments for the Future” programme.• PIONEER Project for Precision Immuno-Onco-

logy for advanced Non-Small Cell Lung Cancer Patients with PD-(L)1 ICI Resistance (PI : Prof. F. Barlesi, AMU/AP-HM);

• LUMIERE project for LUng cancer and Micro-biota Interactions for Immunotherapy Efficacy in REfractory patients (PI : Prof L. Zitvogel, Gus-tave Roussy).

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Places of Worldwide Inves-tigations

Our research is led in two early-stage biotech units that have the freedom and flexibility to do things dif-ferently and are able to explore novel science and emerging technologies. - The Innovative Medicines and Early Development Biotech Unit is AstraZeneca’s global research and early development, focusing on small molecules, oligonucleotides and emerging drug platforms. MedImmune is responsible for our global biologics R&D. Both IMED and MedImmune are responsible for delivering projects to GMD for late-stage development.• Our late-stage Global Medicines Development

(GMD) unit has developed world-leading capa-bilities to deliver extensive multi-country, multi-site clinical trials involving many thousands of patients.

Our strategic R&D centres.


IND

US

TR

IEL

S

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Professional InfoStrategic Collaborations Partnership Manager, Headquarters Medical Oncology

Experience• Strategic Collaborations Partnership Manager,

Headquarters Medical Oncology, Bristol-Myers Squibb2018 - Present

• Associate Medical Director, Immuno-Oncology, Bristol-Myers Squibb2016 - 2017

• Disease Area Specialist, Immuno-Oncology, Bristol-Myers Squibb2015 - 2016

• Medical Science Manager, Immuno-Oncology, Bristol-Myers Squibb2009 - 2014

• Medical Communication, Pfizer2009

EducationMaster in management of pharmaceutical in-dustry, Burgundy School of Business 2008 - 2009

[email protected]

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Professional InfoInternational Immuno-Oncology Network (II-ON) Research Liaison

Experience• Immuno-Oncology Research Liaison, Early Cli-

nical Development, Bristol-Myers Squibb2017 - Present

• Management Consultant\BD Manager, The Solution Lab, Inc.2016 - 2017

• Postdoctoral Fellow, Memorial Sloan Kettering Cancer Center2014 - 2017

• Postdoctoral Fellow, NYU Langone Medical Center2013 - 2014

EducationUniversité d’Auvergne (Clermont-Ferrand II)Ph.D., Molecular oncology, 2009 – 2013

University of California Los Angeles / Université d’Auvergne (Clermont-Ferrand I)MS/BS, Molecular Genetics

[email protected]

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Professional InfoDisease Area Specialist Thoracic Oncology – France

Experience• Disease Area Specialist Thoracic Oncology,

Bristol-Myers Squibb-France2016- Present

• Disease Area Specialist Melanoma, Bristol-Myers Squibb-France2015

• Medical Science Manager Immuno-Oncology Bristol-Myers Squibb-France2014

• Senior Post-doctoral Fellow Oncology, Institut Curie, France 2012- 2014

• Associate Scientist Oncology, University of Miami, USA2011

• Associate Scientist Oncology, MD Anderson Cancer Center, USA 2008-2011

EducationPhD in Cancer Biology, University of Texas 2009 – 2012

Master of Business Administration, University of Paris I (IAE)2005

Pharm D, University of Paris XI 1998- 2004

[email protected]

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Professional InfoDisease Area Specialist Thoracic Oncology – France

Experience• Senior Director, Immuno-Oncology Discovery

Research, Bristol-Myers Squibb2016 - Present

• Senior Scientific Director, Discovery Head Pros-tate Cancer Disease Area, Immuno-Oncology Discovery Research, Janssen2015 - 2016

• Principal Scientist, Immuno-Oncology Disco-very Research, Janssen2014 - 2015

• Scientist III/Group Leader, Immuno-Oncology Discovery Research, Bristol-Myers Squibb2011 - 2014

• Scientist I, Preclinical Oncology, MedImmune2009 - 2011

• Post-doctoral Research Fellow, Dana Farber Cancer Institute/Harvard Medical School2008 - 2009

EducationDuke UniversityPh.D., Immunology, 2003 - 2008

[email protected]

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Professional InfoDirector, Strategic Collaborations, Headquarters Medical Oncology

Experience• Director, Strategic Collaborations, Headquarters

Medical Oncology, Bristol-Myers Squibb2015 - Present

• Head of External Relations and Partnerships, French Foundation for rare diseases2013 - 2015

• Head of International affairs and grants office, CBM - Cluster in biomedicine2008 - 2013

• Advisor to the Director-General for the Inter-nationalisation of research, Italian Ministry of Education, University and Research2005 - 2008

• Senior financial auditor, Ernst & Young2002 - 2005

• Financial auditor, Arthur Andersen2001 - 2002

EducationPhD, Cellular and Molecular Biology, Gustave Roussy and Pierre et Marie University1998 - 2001

[email protected]

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Professional InfoDisease Area Specialist Melanoma

Experience• Disease Area Specialist Melanoma, Bristol-

Myers Squibb-France2016 - Present

• Medical Science Manager, Immuno-Oncology, Bristol-Myers Squibb-France 2014 - 2016

• Scientist post-doctoral, translational oncology, Inserm, Paris, France2012 - 2013

• Research fellow, Memorial Sloan Kettering Cancer Center, New York, USA2009 - 2012

EducationPhD. Pharmaco-genomics oncology, Institut de Cancérologie Gustave Roussy, Villejuif, and uni-versité Paris Descartes, France2003 - 2008

Science industry business & management, New York Academy of Sciences, USA2011

[email protected]

Racim BOUABDALLAHMD

Alexis DESRICHARDPhD

Amaury DUMONTPhD

Michael QUIGLEYPhD

Luigi RAVAGNANPhD

Nabahet AMEURPhD


IND

US

TR

IEL

S

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Professional InfoManager, Immuno-Oncology, Business Develop-ment

Experience• Manager, Immuno-Oncology, Business Deve-

lopment, Bristol-Myers Squibb2016 - Present

• MBA Rotational Associate, Bristol-Myers Squibb2015 - 2016

• Postdoctoral Fellow, University of Pittsburgh2008 - 2012

EducationCarnegie Mellon University, Tepper School of BusinessM.B.A., 2013 - 2015

Georgia Institute of TechnologyGeorgia Institute of TechnologyPh.D., Biomedical Engineering, 2001 - 2007

[email protected]

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Professional InfoDisease Area Specialist early assets / emerging tumors-France

Experience• Disease Area Specialist Genito-urinary mali-

gnancies, Bristol-Myers Squibb-France2016 - 2017

• Medical Advisor Immunology/Rheumatology, Novartis Pharma-France2016

• Medical Affairs Expert Immunology/Transplan-tation, Novartis Pharma-France2013 - 2015

• Pharmacology department manager-Immuno-therapy, Invectys SA-France2011 - 2013

EducationMaster in Methodology and Analysis of clinical trials, Université Lyon I - Claude Bernard2015 - 2016

PhD in Immunology/vaccinology, Université Pierre et Marie Curie, Paris2007 - 2010

Trinational Engineer school in Biotechnolo-gies (Ecole Supérieure de Biotechnologies de Strasbourg)-Strasbourg (F), Freiburg/Karlsruhe (D), Basel (CH)2004 - 2007

[email protected]

Fang ZHANGPhD, MBA

Christelle ROSSIGNOL-LIARDPhD

Company name: GLAXOSMITHKLINECompany size: 100 000 employeesNumber of countries: Present in 150 countriesAnnual sales: $31,6 billion EurosR&D investment: $4 billion Euros in 2016

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

COMPANY DESCRIPTION

GSK is a science-led global healthcare company.We have three world-leading businesses that research, develop and manufacture innovativepharmaceutical medicines, vaccines and consu-mer healthcare products.We invest in scientific research and discovery to develop innovative products and are committed to widening access to our products, so more people can benefit, no matter where they live in the world or what they can afford to pay.We are transforming how we work and challen-ging industry norms to better meet patient needs.We Collaborate with partners combining exper-tise to accelerate progress.We are on a mission to help people do more, feel better, live longer.Our main therapy areas are Respiratory, Vaccines, HIV/infectious diseases, Immunoinflammationand Oncology.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


GSK Oncology R&D has established a focused effort in Immuno-Oncology, Epigenetics and CellTherapy. Chemists, biologists, physicians and other scientists are responsible to studymolecules from Discovery through early stage clinical trials.Oncology R&D prioritizes research in key areas that may offer new hope for discoveringmedicines that can help patients living with can-cer, with long-term survival or cure asobjective.With this goal in mind, our scientists are focused on trying to answer today’s importantquestions in cancer research and use combina-

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Marc S Ballas, MD, MPH is a medical oncolo-gist/hematologist who graduated from Albert Einstein College of Medicine (Bronx, NY), then attended internal medicine residency at Monte-fiore Medical Center (Bronx, NY) and fellowship at National Institute of Health (Bethesda, MD). He subsequently joined New York University Langone Cancer Center (NYC, NY) as an assistant professor

tions that might be of therapeutic advantage.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


Not applicable since our divestment to Novartis of our commercialized oncology products we don’t have any commercialized product in oncology.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

R&D Focus Portfolio and Prospective in this areaR&D oncology clinical por-folio

• GSK2857916 BCMA antibody drug conjugate - Phase I - Multiple myeloma

• GSK3359609 ICOS agonist antibody - Phase I - Solid tumors

• GSK3174998 OX40 agonist mAb - Phase I - Solid tumors, Heme malignancies

• GSK1795091 TLR4 agonist - Phase I - Solid tumors

• GSK3377794 NY-ESO-1 TCR transduced T cells (HLA-A0201) - Phase I/II - Sarcoma, Multiple

• myeloma, NSCLC, Ovarian cancer, Melanoma

Marc BallasMD

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Director Translational Sciences, Immuno-onco-logy, GSK

Sara Brett earned her doctorate in Immunology at University of London and has extensive expe-rience in tumour immunology, Infectious Disease Immunology, and Immune-Inflammation in aca-demia and industry.

She has led translational research programs for Biopharms, Vaccines and Adoptive T cell thera-pies over the last 20 years at GlaxoSmithKline and has authored several publications. More recently she has played a key role in the Immuno-Onco-logy and Combinations department, developing a patient selection platform to provide an integrated understanding of human ex vivo, and in vitro sys-tems to aid tumor selection, patient stratification, and rationale for combination approaches for Immune-oncology assets.

[email protected]

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Sara BrettPh.D

in Thoracic Cancers and sarcoma before joining the pharmaceutical industry.

At Bristol Myers Squibb, he led ipilimumab monotherapy and ipilimumab + chemotherapy studies in lung and ovarian cancers. Later, he joined AstraZeneca leading the durvalumab early lung cancer program (Atlantic, Arctic, Pacific, & Ocean11). Since June 2017, he has joined at GlaxoSmithKline R&D leading studies across the GSK portfolio in epigenetic, immune oncology, and cell therapy in thoracic as well as liquid tumors.

[email protected]

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


IND

US

TR

IEL

S

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Medical manager oncology, GSK FranceSince 2014 in charge of several projects in onco-logy (Medical affairs and Clinical Research) :Launch of VEGFinhibitor Pazopanib in renal cell carcinoma,Early access program of MEKi Trametinib/BRAFi Dabrafenib combination in melanomaEarly phase clinical trials:

• FAKinhibitor, Solid tumors• BETinhibitor, Solid tumors FTIH• LSD1 inhibitor, SCLC• EZH2 inhibitor, NHL• ICOS agonist, monotheray and combination,

Solid tumors

From 2000 to 2014 at GSKClinical research projects in several therapy areas: HIV, Neurology, Ophthalmology, Obstetrics, Thrombocytopenia.

Training backgroundMedical degree from Algiers University, school of medicine.Residency in Ophthalmology Algiers University.University degree in Clinical Research Lariboi-sière school of medicine, Paris.University degree in molecular medicine in onco-logy Pierre et Marie Curie University, Paris.

[email protected]

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Medical Director Specialty Products, Clinical Re-search & Academic Alliances.

Training and academic backgroundMD degree from the medical school (University of Nancy/ France).University diplomas in clinical pharmacology, Infectious diseases and Nutrition.

Industry background1992-1997: Cardiovascular medical project lea-der (Rhone-Poulenc-Rorer).1997-2000: International Cardiovascular medical director ( Aventis).2000-2005: Cardiovascular and Anesthesia me-dical Director (AstraZeneca).Since 2005 GSK: Therapeutic Area medical direc-tor (HIV & infectious diseases, then cardio-vascular, metabolic, neurosciences & rare diseases) and cur-rently Medical Director Specialty Products, Clinical Research and Academic Alliances.

Aeras of interestTranslational, Early & Late phase Clinical Research (Metabolic, Immuno-inflammation & infectious di-seases, rare diseases, neurosciences and oncology)Public-Private Partnerships.

[email protected]

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Jorge Kirilovsky was born in 1956 in Buenos Aires (Argentina). He obtained his Ph.D. in Biochemistry in 1986 at the Hebrew University of Jerusalem, Israel where he studied the role of lipids in the mechanism of action of the b-adrenergic recep-tor. Recipient of a post-doctoral fellowship from EMBO, Jorge moved to Paris in 1986 to work at the Pasteur Institute on neurotrophic factors involved in the development of the neuromus-cular junction. In 1988, Jorge joined the Glaxo Research Center located at Les Ulis, France as an investigator in the Biology group working on signal transduction pathways.

In 1990, he became leader of a unit devoted to research in immunoregulation and progressively shifted to the cardiovascular field covering dysli-pidemia, hypertension, cardioprotection and heart failure as his main areas of research. Among the main achievements of that period, Jorge and his team were involved in the discovery of the PDE5 inhibitor Tadalafil, currently marketed as CialisTM. After being appointed Head of the Biology Depart-ment in 1996, he became Vice-President and Head of the François Hyafil Research Center of GSK in 2006 and subsequently named Head of the Lipid Metabolism Discovery Performance Unit in 2008.The team led by Jorge discovered a series of BET inhibitors. The lead compound was the first mole-cule targeting an epigenetic mechanism to be in clinical trials, currently investigating the potential of this target in cancer. Jorge was appointed Head of the Flexible Discovery Unit in 2012. As such, Jorge led a group of 70 chemists, biolo-gists, pharmacokineticists and clinicians working in the discovery of transformational medicines for a broad range of therapeutic indications in partnership with other groups of GSK R&D with special emphasis in academic teams and seeding new scientific concepts.

Since 2012, the team led by Jorge contributed to the commitment of 2 human studies by GSK R&D, the discovery of 8 candidates and 12 pre-candidates to clinical development. At the end of 2016 Jorge became VP, Head of Flexible Discovery Unit Exter-nalization Projects in charge of the development of

Naïma KerboucheMD

Nadine Weisslinger-DarmonMD

Jorge Kirilovsky

academic partnerships in emerging markets.In addition, since 2009 he is a member of the Scientific Committee of InnoBio Fund and in 2015 was appointed to chair the Committee for one year. He is also a member of the Executive Committee of the Association for Research and Innovation of Health Industries in France (ARIIS) where he is in charge of the ARIIS/INSERM Inno-vation Summer School.

[email protected]

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Company name: IPSENCompany size: 4 500 employeesR&D Staff: 900 employeesAnnual sales 2015: € 1.4 billion

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

COMPANY DESCRIPTION

Ipsen is a global specialty-driven pharmaceutical company committed to the treatment of targeted debilitating diseases. Its development strategy is supported by three franchises: neurology, endo-crinology and urology-oncology. Ipsen also has a significant presence in primary care. Ipsen’s R&D is focused on its innovative and differentia-ted technological platforms, peptides and toxins. In 2015, R&D expenditure totaled close to €193 million, representing close to 13% of Group sales.

The Group has an active policy of partnerships. Indeed, since its inception, Ipsen has consistently implemented an open Research and Develop-ment strategy to nurture its own innovation capa-cities. These networks are built around Ipsen’s areas of expertise in endocrinology, neurology and oncology.The goals of these partnerships are to streng-then Ipsen’s R&D innovation capacity, notably by giving access to new and promising technologies and support the exploration of new research fields. Therefore, the Group has strategically es-tablished its R&D sites in geographical proximity with highly regarded university research centres, enabling the teams to access the best science & innovation:

i) The Research and Development Centre at Les Ulis (France) is close to Paris-Saclay campus. The scientists are focused on drug discovery of novel medicines in the fields of neurology and oncology.

ii) The Research and Development Center newly established in Cambridge (Massachusetts, United States) reinforces its leadership in the field of peptides and its open-innovation strategy with proximity of world-class academic centers and biotechs.

iii)The Research Center in Oxford (UK) is focused on the discovery of new modified recombinant

botulinum toxins, mainly for neurology indica-tions.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


Ipsen’s mission, “innovation for patient care”, highlights the Group’s determination to focus on patients and unmet medical needs and to provide innovative therapeutic solutions. Focusing on patients is critical to determine unmet medical needs and identify both the pathophysiological mechanisms and biological targets that should be developed.

In neurology, while not working in psychiatric di-sorders, the Group is a key player in the treatment of movement disorders (spasticity, dystonia, dys-kinesia,…). Ipsen is committed to improving the mobility, autonomy and quality of life of patients with these very disabling motor disorders. In this field, The Group’s commitment to developing neurotoxins dates back more than twenty years.

The acquisition in 2013 of Ipsen Bioinnovation (formerly Syntaxin), a leader in the engineering of recombinant toxins, allows Ipsen access to inno-vative technologies and to develop a complete portfolio of toxins. Those efforts to develop new Botulinum toxins with improved properties are associated with prospects for new formulations and delivery approaches of toxins to better res-pond to patients needs. Ipsen also develops small molecules programs in Parkisonism and Hunting-ton’s disease, neurodegenerative diseases pres-enting as well movement disorders.

In addition to movement disorders, Ipsen ad-vances programs for pain and neurogenic bladder overactivity.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

PRODUCT PORTFOLIO IN THIE AREA OF NEUROS-CIENCES

Dysport®: is based on botulinum toxin ‘Type A’, a compound based on a bacterium that inhibits the transmission of nerve impulses to the muscle. Botulinum toxin injections cause contracted muscles to relax, enabling patients to return to a number of their daily activities, while relieving them and improving their quality of life. Dysport® presents a diverse range of drug indications:

• Spasticity (exaggerated muscular tone fol-lowing a stroke for example). For example, Dys-port® was recently approved by FDA for injec-

tion for the treatment of Lower Limb Spasticity in children aged two and older

• Cervical dystonia (a chronic condition in which the neck is deviated),

• Hemifacial spasm (a movement disorder cha-racterized by contractions of the muscles loca-ted on one side of the face that can lead to disfigurement),

• Blepharospasm (involuntary contraction of the eyelids).

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

R&D FOCUS PORTFOLIO AND PROSPECTIVE IN THIS AREA

BN82451B (Phase IIa) – this molecule is cur-rently in clinical development in Huntington’s disease and has completed a phase I clinical pharmacology trial. A Phase IIa clinical proof of concept of BN 82451B in Huntington Disease patients is currently underway in Germany. This molecule is simultaneously able to exert multiple pharmacological activities and is designed to pro-tect the mitochondria.

VSN16R (Phase IIa): VSN16R is a novel, orally active small molecule compound developed by Canbex Therapeutics Ltd (Canbex) and intended for the treatment of spasticity in Multiple Scle-rosis and other disorders. Preclinical and Phase I clinical studies have demonstrated that VSN16R has the potential to provide substantially better patient care than existing systemic anti-spastic treatments. In February 2015, Ipsen and Canbex announced that Canbex has granted Ipsen an op-tion giving Ipsen the exclusive right to purchase 100% of Canbex shares upon completion of the Phase IIa study of VSN16R.

LRRK2 kinase inhibitors (Pre-clinical phase) – Ipsen has entered in 2012 into a research colla-boration with Oncodesign to discover and develop innovative LRRK2 kinase inhibitors as potential therapeutic agents against genetic forms of Par-kinson’s Disease.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

PLACES OF WORLDWIDE IN-VESTIGATIONS

Worldwide.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


IND

US

TR

IEL

S

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Training and academic backgroundMedical DoctorPost-graduate degree in Clinical ToxicologyPost-graduate degree in PharmacovigilancePost-graduate certificate in Statistics in Clinical ResearchExecutive MBA – Ashridge (UK)

Industry backgroundMember of Merck Executive Committee in France.Responsible for Merck Medical Affairs, in France, in all Therapeutic Areas (Oncology, Neurology, Fertility, Endocrinology and Primary Care) and Medical Excellence which includes Medical Infor-mation and Patient Approach programsEnsure the safe and appropriate use of Merck medicines for the benefits of patients, turn data into applied knowledge and healthcare solutions for HCPs, provide scientific knowledge and exper-tise to support commercial teams and implement clinical development strategies locally.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Training and academic backgroundErbitux & GI cancer portfolio LeadBiopharma - R&D - Global Medical Affairs Oncology

Industry backgroundReceived his MD degree in 1987 and completed his residency in Oncology and board certification in Clinical Oncology from Institut Gustave RoussyJoined the French affiliate of the German com-pany ASTA Medica in the mid 1990s to support WHO Essential Medicines cyclophosphamide and ifosfamide. Then from 2000 after acquisition by Baxter, led as Director of Global Oncology.Joined Abraxis Bioscience in 2007 as VP Europe and led the registration, pricing and launch of Abraxane® in G5 as a non-substitutable taxane in advanced breast cancer.From 2013 joined Merck KGaA in HQ Darmstadt, and led as Senior Medical Director in GMA with responsibilities of evofosfamide.Appointed Erbitux® Asset Lead in 2016.Appointed GI Indication Lead in 2017.

ContactMerck KGaAFrankfurter straße 250, 64293 Darmstadt,GermanyT. +49 6151 7251262M. +49 151 145 [email protected]

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Training and academic backgroundPhD in Human Biology (reproduction endocrinology)Master in EpidemiologyMaster in Statistics applied to medicineMaster in Metabolisms, Endocrinology and Nutrition

Industry backgroundCurrently at the Medical Affairs Direction, after 5 years experience in the Public Affairs and Mar-ket Access Department at Merck , and almost 10 years in the MAPI Group (Late phase CRO specia-lized in pharmacoepidemiology).

Responsible for the Medical Excellence team which gathers the medical information, the me-dical operations, the patients approach and the pharmacoepidemiology expertise.

Skills and experience: Epidemiology, pharmacoe-pidemiology, market access, patient-reportedoutcomes, clinical trials, pharmacoeconomics, oncology, neurology, fertility, endocrinology.

ContactMerckDirection des Affaires Médicales37 rue Saint-Romain, 69008 Lyon, FranceT: +33 (0)4 72 78 26 67M: +33 (0)7 60 64 24 [email protected]

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Sylvie CHABACMedical Affairs Director, Biopharma France

Jean-François GIMONETMDErbitux & GI cancer portfolio LeadBiopharma - R&D - Global Medical Affairs Oncology

Juliette LONGINPhD. Medical Excellence Manager

is tested in nine ongoing pivotal studies across different cancer types, like gastric cancer, lung cancer (NSCLC), urothelial cancer, renal cancer, ovarian cancer, and head & neck cancer.

Another molecule of the clinical immuno-onco-logy portfolio is M7824 (anti-PD-L1/TGF-β trap), a potentially first-in-class bi-functional immu-notherapy, designed to simultaneously block two immuno-inhibitory pathways (PD-L1 and transforming growth factor beta) that are com-monly used by cancer cells to evade the immune system. The aim of this investigational drug is to control tumor growth by restoring and enhancing anti-tumor immune responses.

> Remark: Pipeline products are under clinical investigation and have not been proven to be safe and effective. There is no guarantee any product will be approved in the sought-after indications.

ContactContact MerckDirection des Affaires Médicales37 rue Saint-Romain, 69008 Lyon, FranceM. +33(0)6 80 99 27 [email protected]

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Company name: MERCKNumber of countries: Present in 66 countriesAnnual sales: $15 million Euros 2016R&D investment: $2 million EurosHeadquarters: Darmstadt (Germany)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

COMPANY DESCRIPTION

Merck is a leading science and technology compa-ny in healthcare, life science and performance ma-terials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions.

Founded in 1668, Merck is the world’s oldest phar-maceutical and chemical company. The founding Merck family remains the majority owner of the publicly listed corporate group Merck, Darms-tadt, Germany, and holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada where it operates as EMD Serono in the Biopharma business, as Millipore Sigma in the Life Science business, and as EMD Performance Materials in the materials business.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


Merck has a long-term commitment to deve-loping innovative treatments to help manage neurodegenerative diseases such as multiple sclerosis (MS).We are also deeply committed to changing the cancer landscape. Our immuno-oncology (iONC™) research and early development plat-form, integrating research, early development and biomarker strategies, focuses on discovering and developing potential new therapies that are intended to harness the immune system and activate or augment the body’s natural anti-tu-mor response.Besides Merck Healthcare division holds a strong and diverse portfolio of compounds andtechnology in fertility, endocrinology and general medicine.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


Erbitux® (cetuximab) is a highly active IgG1 mo-noclonal antibody targeting EGFR. As amonoclonal antibody, the mode of action of Erbi-tux is distinct from standard non-selectivechemotherapy treatments in that it specifically targets and binds to the EGFR. This binding inhibits the activation of the receptor and the subsequent signal-transduction pathway, which results in reducing both the invasion of normal tissues by tumor cells and the spread of tumors to new sites. It is also believed to inhibit the abi-lity of tumor cells to repair the damage caused by chemotherapy and radiotherapy and to inhibit the formation of new blood vessels inside tumors, which appears to lead to an overall suppression of tumor growth. Due to the structure of IgG1, cetuximab is acting on the adaptive and innate immunity through NK cell antibody-dependent cellmediated cytotoxicity (ADCC).Erbitux has already obtained market authorization in over 90 countries world-wide for thetreatment of colorectal cancer and for the treat-ment of squamous cell carcinoma of the head and neck (SCCHN).

As early adopters of precision medicine, we take a biomarker-led approach to ensure the right pa-tients receive the right drugs at the right time. At Merck, we have a legacy of providing biomarker-driven therapy with ERBITUX® and RAS testing in mCRC.

Our collaborations with Sysmex Inostics, Biocar-tis and AmoyDx led to the development of the world’s first liquid biopsy RAS biomarker tests. These collaborations aim to improve mCRC pa-tients’ access to RAS testing with highly innova-tive, approved liquid biopsy tests, to ensure that each patient receives the best treatment even if biopsy material is not available.

The Sysmex Inostics and AmoyDX liquid RAS bio-marker biopsy test technologies both received CE Mark approval in 2016. The Biocartis liquid RAS biomarker biopsy test technology is expected to re-ceive CE Mark approval in the second half of 2017.

Companion Diagnostics (CDx) PartnershipsWe have CDx partnership agreements with Dako (Agilent), Life Technologies (ThermoFisher) and HTG Molecular for the development of CDx for several oncology programs.

Our collaboration with Dako includes the co-de-velopment of a potential anti-PD-L1 CDx as part

of Merck’s strategic alliance with Pfizer for ave-lumab.

We have a strategic partnership with Illumina for the development of a universal next-generation sequencing-based oncology diagnostic for cli-nical trials of targeted cancer therapies, which will be able to serve as a CDx assessing several alterations, in multiple oncology indications for multiple drugs.

Building on new discoveries made by our research team, we are also doing innovative work in the field of immuno-oncology.

Bavencio® (avelumab) is a human anti-program-med death ligand-1 (PD-L1) antibody. Avelumab has been shown in preclinical models to engage both the adaptive and innate immune functions. By blocking the interaction of PD-L1 with PD-1 receptors, avelumab has been shown to release the suppression of the T cell-mediated antitu-mor immune response in preclinical models. Avelumab has also been shown to induce NK cell-mediated direct tumor cell lysis via antibo-dy-dependent cell-mediated cytotoxicity (ADCC) in vitro. In November 2014, Merck and Pfizer announced a strategic alliance to co-develop and co-commercialize avelumab. Just two years after this formation, Bavencio has been approved in the US for Merkel Cell Carcinoma (MCC) and bladder cancer, as well as in Switzerland, EU and Japan for MCC.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


“Taking on the world’s most challenging me-dical conditions” As a science-driven organization, we are delive-ring a transformative pipeline that makes a real difference for patients, with a strong focus on helping to create, improve and prolong lives.Our core areas of research include:

• Immunology• Oncology• Immuno-Oncology

The current R&D immuno-oncology portfolio comprises therapeutic candidates in early clinical development and a pipeline of preclinical mole-cules including avelumab, a fully human anti-PD-L1 IgG1 monoclonal antibody thought to enable the activation of T-cells and the adaptive immune system. As of November 01, 2017, Avelumab


IND

US

TR

IEL

S

Company name: MSDCompany size: 68 000 employeesNumber of countries : more than 140 countriesAnnual sales 2015: $39,5 billionR&D investment $6.6 billionHeadquater: Kenilworth, New Jersey, USA

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

COMPANY DESCRIPTION

MSD is a global leader in delivering innovative health solutions through its medicines, vaccines, biologic therapies, consumer and animal health products. MSD also demonstrate its commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. MSD is known as Merck in the United States and Canada.MSD product offering categories include heart and respiratory health, infectious diseases, dia-betes, cancer,inflammatory diseases and wo-men’s health.MSD focus research on conditions that affect mil-lions of people around the world - diseases like Alzheimer’s, diabetes and cancer.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


Since 1891, our researchers have helped to find new ways to treat and prevent illness — from the discovery of vitamin B1, to the first measles vaccine, to cold remedies and antacids, to the first statins to treat high cholesterol. Today, as a research-intensive biopharmaceutical company, we’re focused on making important scientific ad-vancements within hepatitis C, HIV, diabetes and immuno-oncology, Alzheimer desease. While we are proud of our past, we are enthusiastic about the future. We aim to create a healthier, brighter future for people around the world.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

PRODUCT PORTFOLIO IN THIE AREA

Today, Merck has more than 50 prescription products in key therapeutic areas, such as cardiovascular disease, respiratory disease, oncology, neuroscience, infectious disease, immunology and women’s health.

For more information http://www.merck.com/product/home.html

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

R&D FOCUS PORTFOLIO AND PROSPECTIVE IN THIS AREA

Several research programs: In neurosciencesAlzheimer’s Disease : an inhibitor of beta-site amyloid precursor protein cleaving enzyme 1 (BACE) that is being evaluated in clinical trials for the treatment of Alzheimer’s disease (Phase III).

Overview on MERCK R&D pipeline :15 PHASE II PROGRAMS• Advanced solid tumors• Asthma• Cough• Diabetes• Heart Failure• Hepatitis C• Hodgkin Lymphoma• Liver Cancer• Nasopharyngeal Cancer• Ovarian Cancer• Pneumoconjugate Vaccine• Primary Mediastinal Large B-Cell Lymphoma• Prostate Cancer

19 PHASE III PROGRAMS• Alzheimer’s disease• Atherosclerosis• Bacterial Infection• Bacterial Pneumonia• Bladder Cancer• Breast Cancer• CMV Prophylaxis• Colorectal Cancer• Diabetes• Ebola Vaccines• Esophageal Cancer• Gastric Cancer• Head and Neck Cancer• Herpes Zoster Vaccine• HIV• Multiple Myeloma

6 UNDER REVIEW• Allergy• C Difficile Infection• Diabetes• Head and Neck Cancer• Lung Cancer

For more information on the entire MSD research program.http://www.merck.com/research/pipeline/home.html

MSD’s research and clinical development pro-gram is global and involves countries and scien-tific leaders from:North America, Europe, South America, Africa, Australia, and Asia.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Previous experiencesMedical Advisor in Rheumatology, Anesthesia, at MSD France.Project Manager at HAS (HTA).Physician at Biosys, biotech producing monoclo-nal antibodies.

ContactNawel YAKOUBIMSD France 34 avenue Léonard de Vinci I 92418 COURBEVOIE Cédex I FRANCE

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Nawel YAKOUBIManager of Scientific Partnerships at MSD France

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Training and academic backgroundPharmDMASTER 2 of Health and Pharmaceutical Engi-neering specialized in Clinical Evaluation -Pharmaceutical Medicine

Industry backgroundClinical trial manager in CRO (MAPI) and MerckMedical advisor in Oncology since 8 years for Merck (mCRC, SCCHN, NSCLC and pipeline).Currently working on the Merck pipeline : prepare launches and work closely with Global/Regional team to identify key partnership linked to Pipeline products.

ContactMerckDirection des Affaires Médicales37 rue Saint-Romain, 69008 Lyon, FranceT. +33 (0)4 72 78 28 44M. +33 (0)6 68 40 12 [email protected]

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Training and academic backgroundPhD in Molecular BiologyEngineering DegreeEpidemiology Degree

Industry backgroundAfter years in academic research, in the pharma-ceutical company since 24 years (scientist group leader, contract manager, product and marketing manager) covering several therapeutic areas (oncology, neurology, osteoporosis).Currently working in the Medical Affairs Depart-ment as medical operation manager. In charge of insuring optimal quality and methodologies in medical excellence, and develop real world evi-dence by valorizing pharmaco-epidemiological data.Skills and experience: identify disease-related genetic targets for drug screening, clinical trials, patient support services.

ContactMerckDirection des Affaires Médicales37 rue Saint-Romain, 69008 Lyon, FranceT. +33 (0)4 72 78 28 35M. +33 (0)6 71 29 33 [email protected]

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Training and academic backgroundPhD in BiochemistryMaster in Business Administration

Industry backgroundCurrently, Uwe is the Head of Scientific Competi-tive Intelligence at Merck Biopharma R&D where he is going to establish a central, customer fo-cused organization which delivers insights that informs strategic decisions. His previous roles at Merck included the Head Portfolio & Business Strategy Immuno-Oncology R&D as well Global Head of R&D Finance & Controlling.

Prior to joining Merck KGaA, Uwe worked for more than 12 years in different Management positions in the area of Research & Development mainly in the Life Science but also in the Consultancy and Software Industry.

ContactMerck KGaAFrankfurter straße 250, 64293 Darmstadt,GermanyT. +49 6151 72 38171M. +49 151 1454 [email protected]

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Audrey SERONDEPharmD. Oncology Product Medical Manager

Benoît Van HILLEPhD. Medical Operation Manager

Uwe-Peter WEITZELPhD. MBA.Head Scientific Competitive Intelligence - Exter-nal InnovationBiopharma - Global Research & Development


IND

US

TR

IEL

S

Company name: PFIZERCompany size: 97 000 employeesNumber of countries: Present in 175 countriesAnnual sales: $49 billionR&D investment: $7.7 billion

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

COMPANY DESCRIPTION

Working together for a healthier world® At Pfizer, we apply science and our global re-sources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer health care pro-ducts.

Every day, Pfizer colleagues work across deve-loped and emerging markets to advance well-ness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care pro-viders, governments and local communities to support and expand access to reliable, affordable health care around the world.

For more than 150 years, we have worked to make a difference for all who rely on us. We rou-tinely post information that may be important to investors on our website at www.pfizer.com. In addition, to learn more, please visit us on www.pfizer.com and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube, and like us on Facebook at Facebook.com/Pfizer.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


We aim to significantly improve the lives of can-cer patients worldwide with approved therapies for a broad array of cancers. Our robust pipeline

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Melissa M. Fitzgerald, Ph.D. is a Senior Director, Oncology for Pfizer’s External Science & Inno-vation ES & I) group. In this role, Melissa leads scouting efforts for the CSO of Tumor Cell Biology/Immuno Biology, and helps expand and manage partnerships with key academic institutes, start-ups and biotech companies in areas of scientific interest for the CSO.

Melissa brings to ES & I’s Oncology Scouting team her enthusiasm for promoting innovation, gained through fifteen years of research and corporate development experience in the San Diego Life Sciences eco-system. Following her Ph.D. in Physical Chemistry from Virginia Com-monwealth University, Melissa was a post-doc in the Department of Molecular Biology at the Scripps Research Institute in La Jolla. She then held positions of increasing responsibility at Dura Pharmaceuticals (acquired by Elan Pharmaceu-ticals), DermTech International, UC San Diego’s Technology Transfer office, UC San Diego’s Ins-titute for Genomic Medicine (founding team), and Amylin Pharmaceuticals (acquired by Elan).

At Amylin, Melissa was an Associate Director-Business Development, where she led the search and evaluation team for early stage technologies, and completed a number of acquisitions, licenses and collaboration agreements.

She joined Pfizer in 2011 in a Global Scouting role, expanded to Oncology Precision Medicine in 2015, and to Tumor Cell Biology scouting res-ponsibilities in 2017.

of novel medicines will help with our goal to deli-ver meaningful therapies that transform the can-cer treatment landscape.

At Pfizer, we strive to bring innovative treatments to the forefront by developing therapies that pro-vide maximum efficacy while minimizing adverse effects for the patient. Our current portfolio of oncology therapies covers a range of cancers. We continue to study these therapies alone and in combination with other treatments to fully explore their ability to improve the lives of cancer patients.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


As an emerging player in next-generation IO science, we recognize the urgency of our mission to help patients in need of anti-cancer alterna-tives. As of April 2017, we have 11 compounds in ongoing IO clinical trials. And that’s just the beginning. Going forward, we are committed to bringing novel IO agents into the clinic. Explore the assets in our IO product pipeline: https://www.pfizer.com/science/drug-product-pipeline

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


Our Partnering Philosophy Significant innovations with breakthrough impact for patients may be achieved by bringing together the best ideas and minds to turn great science into new medicine. The search for innovative ideas leads to forging partnerships with clear vision, open communica-tion, and a strong collaborative desire to develop outcomes that would not be possible in isolation.

Each partnership is unique, building on the strength of the parties working together to leve-rage significant disease expertise, development capabilities, and the drive to transcend obstacles and deliver solutions. Discover our R&D focus in IO: https://www.pfizer.com/files/partnering/WRD_Brochure.pdf

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


Worldwide, including France.

Melissa M. FitzgeraldPh.D.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Gautam is accountable for shaping Pfizer’s R&D strategy, monitoring and enhancing the value of its pipeline and driving continuous improvement initiatives. At the Divisional and Corporate level, he ensures key R&D decisions are linked to ove-rall strategic priorities, competitive context and financial considerations. He’s a member of the R&D Leadership Team and supports strategic dia-logue with key stakeholders such as the Board, CEO, analysts, shareholders and the scientific community.

Prior to joining Pfizer, Gautam spent ten years at The Boston Consulting Group (BCG), a leading glo-bal strategy consulting firm. As a Senior Principal in the firm’s Healthcare Practice, Gautam worked with a host of Biotech and Pharmaceutical com-panies on high priority issues such as portfolio & innovation strategy, R&D productivity, organiza-tional redesign and post-merger integration.

Gautam earned his M.B.A. from the Indian Insti-tute of Management in Ahmedabad, India, with a focus on Strategy and Finance. He received his B.A. in Economics from St. Stephen’s College at the University of Delhi, India.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Sree Kant leads strategic partnerships and ini-tiatives for Pfizer’s External Science & Innova-tion group, across different therapeutic areas/technologies and geographies. He is focused on innovative partnering models (especially with VCs/Banks, CROs, and Academia) that can drive value for both Pfizer and partner, in new emerging science and technology areas.

Before joining Pfizer, he was a Principal at the Boston Consulting Group advising large pharma and biotech on R&D strategy as well as large M&A. Sree has also worked with two healthcare startups and a generic pharmaceutical company in India and the UK. He has an MBA from the In-dian Institute of Management, and an MPH from the Harvard School of Public Health.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Dr. Patrick is currently the Executive Director and Head of Oncology External Science & Innovation (ES&I) for R&D, as well as the R&D Lead for Stra-tegic R&D Investments (RDI) at Pfizer. The goal of

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Dr. Mohini Rajasagi is Principal Scientist and Re-search Project Leader at Pfizer- Centers for The-rapeutic Innovation (CTI), NY, USA. In the current role, Dr. Rajasagi leads immune-oncology (IO) co-drug discovery programs in collaboration with academic partners. Dr. Rajasagi is also involved in identifying PIs/Biotechs for new partnering activities in the Oncology space. Prior to CTI, Dr. Rajasagi was at Bristol-Myers Squibb, where she led Immuno-Oncology discovery programs in the T and myeloid cell space (pre-clinical discovery to Phase-I) and contributed to translational IO teams to identify novel and relevant biomarkers to pre-dict responses to cancer immunotherapy drugs.

Melissa M. FitzgeraldVP – Strategy, Portfolio, Competitive Intelligence and OperationsWorldwide Research and Development

Melissa M. FitzgeraldGlobal Head – Strategic Partnerships & Initiatives, External Science & Innovation

Melissa M. FitzgeraldPh.D. Head, Oncology External Science & Innova-tion And Strategic R&D InvestmentsExecutive Director

Melissa M. FitzgeraldPhD. Principal Scientist/Research Project Leader Centers for Therapeutic innovationPfizer Worldwide R&Dwww.pfizercti.com

ES&I is to search and evaluate external opportu-nities that are focused on areas that complement Pfizer Oncology Research interests including: targeted immuno-oncology, drug delivery techno-logies, epigenetics, cell cycle and precision me-dicine strategies. Recent executed agreements include BIND Therapeutics, CytomX, Stemcentrx, iTeos, BioAtla, Western Oncolytics and Mediva-tion. Recent equity investments include: Jnana, Adapsyn, Aquinnah, Arrakis, AnTolRx, NextCure, and Metabomed. Denis is an Observer on the Board of Directors for Aquinnah, Arrakis, Next-Cure, and AnTolRx.

Denis received his Ph.D. from the University of Pennsylvania and has worked in several large Pharma oncology organizations, including Merck, DuPont Pharma, GSK and Pfizer. Prior to coming to Pfizer, Dr. Patrick contributed significantly to several oncology drug discovery efforts that lead to the approval of three marketed therapeutic agents including nelarabine, trametinib, and dabrafenib.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


IND

US

TR

IEL

S Dr. Rajasagi holds a PhD degree (Suma Cum Laude) in Cancer Biology with Immunology focus, from German Cancer Research Center, Heidel-berg, Germany. Subsequent to her graduate stu-dies, Dr. Rajasagi pursued her postdoctoral work at Dana Farber Cancer Institute (Harvard Medical School), Boston, USA with Dr. Catherine J. Wu. Dr. Rajasagi spearheaded the systematic identifica-tion and validation of tumor-specific neoantigens through next-generation sequencing, setting the stage for several multi-epitope personalized neoanitgens vaccines based Phase-I clinical trials for tumor immunotherapy.

Dr. Rajasagi’s postdoctoral work on neoantigens has contributed towards the launch of a startup company funded by Third Rock Ventures, Neon Therapeutics in Cambridge, MA, USA. Dr. Rajasagi is lead or co-author in several high impact jour-nals including, Nature Reviews Cancer, Nature Biotechnology and Blood.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Chief Scientific Officer Uwe Schoenbeck leads Pfi-zer’s External Science & Innovation (ES&I) team, part of Worldwide R&D, which seeks to build a premier integrated external portfolio and innova-tive sourcing group to access and progress the best science from academic institutions, industry and biotechs. This global team identifies and establishes partnerships to gain first access to cutting edge science, innovative disease targets, drug candidates as well as platform technologies, from exploratory to clinical proof of concept and covers both small and large molecule approaches together with gene and cell therapies. ES&I main-tains an in-depth network into key scientific glo-bal hubs through a science liaison model serving not only the needs of the Pfizer research units and

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Dr. David Shields is Executive Director and East Coast Site Head for the Pfizer Centers for Thera-peutic Innovation, leading CTI activities in New York, Boston and Europe. Prior to his role at CTI, Dr. Shields was the Director of Oncology Thera-peutics Discovery in focus areas such as immu-no-oncology, epigenetics and cell cycle biology, and was the Research Lead for the Pfizer Pedia-tric Oncology Team. Dr. Shields has held Onco-logy R&D Group Leader positions across portfolio stages from Target Discovery to Translational Research, led Combination and Resistance Stra-tegy for Pfizer Oncology Research and directed pre-clinical translational support for assets such as Sutent (sunitinb), Inlyta (axitinib) and Ibrance (palbociclib).

Dr. Shields holds a Certificate in Medical Labora-tory Sciences from Cork Institute of Technology, a BSc(Hons) in Biomedical Sciences from Univer-sity College Cork, Ireland and a PhD in Bioche-mistry from the University of Alberta, Canada. Subsequent to his graduate studies, Dr. Shields conducted post-doctoral training at The Scripps Research Institute and University of California, San Diego, and was a Research Project Scientist at Moores UCSD Comprehensive Cancer Center.

Dr. Shields is a member of the IMI2 Strategic Go-verning Group for Oncology and is the Pfizer Lead for the public/private ITCC-P4 Pediatric Oncology consortium project.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

The goal of Hilde’s current role is the identification and execution of external partnering and licensing opportunities for Pfizer’s Immuno-Oncology Pro-grams.

Hilde was trained as a cancer biologist, and worked in biotech as a research scientist and group leader on a range of projects, including small molecule cancer drugs, oncolytic viruses, cancer vaccines, and antibodies. She was also an early adopter of new technologies, including mi-croarrays for target discovery, and high-through-put screening methods for GPCRs.

Drawing upon her experience as a scientist, Hilde transitioned to business development and sub-sequently joined Onyx Pharmaceuticals, where she focused on oncology in-licensing and M&A, including search, evaluation, transaction, and strategy. Following the acquisition of Onyx by Amgen, prior to joining Pfizer, Hilde worked as a business development consultant, using her scientific and business background to help clients achieve their BD objectives.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Nathalie ter Wengel, a medical doctor, is the European Head Global Scouting External Science and Innovation at Pfizer, where she is responsible for establishing new collaborations and explo-ring licensing and other corporate development opportunities across all therapeutic areas.

She has an international background and a broad

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Dr. Fan Zhang became a member of Acquisi-tions, Alliances & Licensing team within External Science & Innovation in 2017. He supports the external search and evaluation effort with focus on Immuno-Oncology and Therapeutic Vaccines at Pfizer Worldwide Research and Development. Prior to the current role, Fan was the Immuno-On-cology Asset Team Leader, Thoracic and Hemato-logical Malignancy for PD-L1 checkpoint inhibitor avelumab (Bavencio) within Pfizer-EMD Serono alliance. He also led, coordinated the search and evaluation to support Business Development and licensing effort for avelumab and relevant assets. Intimately involved in 7 announced as-sets partnership (Syndax, Verastem, Transgene, Debiopharm, Vaccinex, Effector Therapeutics, Phosplatin) and many due diligence efforts that will lead to additional soon-to-be announced col-laboration.

Uwe SchoenbeckPh.D. Chief Scientific OfficerExternal Science & Innovation (ES&I) Senior Vice President, Pfizer Worldwide R&D

David ShieldsPh.D. Executive Director Centers for Therapeutic innovationPfizer Worldwide R&Dwww.pfizercti.com

Hilde Stubdal PhD, MBA Executive Director, External Science and InnovationImmuno-Oncology Lead

Nathalie ter Wengel

Nathalie ter WengelPh.D. Immuno-Oncology and Therapeutic Vac-cines LeadAcquisitions, Alliances & LicensingExternal Science & Innovation (ES&I)Pfizer Worldwide Research & Development

R&D strategic priorities, but open to emerging and innovative ideas harvested from its targeted exploration centers, incubators, seed funds and investments vehicles.

Prior to joining Pfizer in 2009, Uwe was Vice Pres-ident, External R&D Innovation for Wyeth Pharma-ceuticals and was a member of the Wyeth’s R&D Executive Committee where he was responsible for developing and implementing Wyeth’s Exter-nal R&D strategy and operations. Preceding his time at Wyeth Uwe served as the Vice President, Cardiovascular Research for Boehringer Ingel-heim in Ridgefield, CT, and was responsible for the global cardiovascular research strategy and drug discovery program from target identification to Pre-Development including life cycle mana-gement for marketed and advanced pipeline products. Prior to joining Boehringer in 2003, he held the position of Assistant Professor of Medicine, Brigham & Women’s Hospital, Harvard Medical School.

Uwe received his degree from the University of Kiel, Germany, and completed postdoctoral trai-ning in the Division of Cardiovascular Medicine, Brigham & Women’s Hospital, Harvard Medical School, before joining as a faculty member.

Uwe has served as a reviewer for multiple peer-reviewed journals (incl. Circulation, Circulation Research, Journal of Clinical Investigation, Journal of Experimental Medicine, Journal of Immunology, Journal of the American College of Cardiology (JACC), Nature Medicine, and the Pro-ceedings of National Academy of Sciences U.S.A.) and has published more than 100 peer-reviewed articles, review articles/book chapters and abs-tracts with particular contributions in areas such as molecular & cell biology, cardiovascular re-search, immunology and metabolism.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

knowledge in the medical field, having worked in the hospital with extensive experience in internal medicine. Nathalie started her commercial career as European Medical Manager at Pfizer, where she successfully led ambitious international projects, combining a business perspective with her medical knowledge. It was this experience, coupled with her father’s illness, that convinced her of the urgent need for change in the pharma-ceutical industry.

Consequently, she started up a company called myTomorrows focused on compassionate use, and served as Chief Medical Officer before joining Galapagos as Business Development Director, where she played a key role in the very success-ful NASDAQ IPO and in partnering filgotinib.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Prior to joining Pfizer in 2015, Fan spent 10 years at Novartis Pharma, successfully fulfilled several roles in Global Product Strategy, Global Program Leadership, Sales Management. His last position was Global Head and Executive Director, Life Cycle Strategy at Novartis Oncology Business Unit.

Fan also served as the Head of International Pro-duct Planning, Global Brand Director for Campath (Alemtuzumab) and Androcur at Bayer Health-care/Bayer-Bracco SpA Joint Venture between 2001-2004. Prior to joining Bayer Healthcare, he served as the Sr. Business Development and Licensing Consultant for Janssen/Ortho Biotech in support of the successful in-licensing of ET-743 from PharmaMar in 2001.

Fan begun his industry career at Sanofi in 1997 and progressed into Sr. Project Manager, Produc-tivity, Portfolio and Project Management

Before he came to US to pursue graduate de-grees, he was the program officer/Diplomatic Attaché, at the Ministry of Science and Techno-logy, Beijing, China between 1985-88.

Fan was also a Post-Doctor at Pfizer after re-ceived his Ph.D in Biopharmaceutics and Clinical Pharmacology from the University of Michigan, Ann Arbor in 1996.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


IND

US

TR

IEL

S

Company name: ROCHE PREDHeadquarters: BASELCompany size: 94 052 employeesNumber of countries: Over 100 countriesAnnual sales 2016: 50 million Swiss francsR&D investment: 9,915 million Swiss francsNet income: 9,733 million Swiss francs

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

COMPANY DESCRIPTION

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with com-bined strengths in pharmaceuticals and diagnos-tics. Roche is the world’s largest biotech com-pany, and is focus on creating truly innovative medicines and diagnostic tests in areas of unmet medical need. Roche is also leader in in vitro diagnostics and tissue-based cancer diagnos-tics, and a front runner in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century.

Twenty-four medicines developed by Roche are included in the WHO Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy. In 2016, the Roche Group employed 94,052 people world-wide, invested 9,915 million Swiss francs in R&D and posted sales of 50,576 million Swiss francs. For more information, please visit roche.com. All trademarks used or mentioned in this release are protected by law.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


Millions of people worldwide continue to suffer from debilitating conditions that have limited treatment options and poor prognosis. At Roche we invest in research and development to trans-form science into medicines and diagnostic tests to address these patient needs. We take a focused approach to increase our chance of

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Training and academic background1996 - 1998: HDR : Ph.D students (HDR) at Uni-versity of Lille HDR in Molecular Pharmacology 1996-1997: Expatriation program at SANTA CLARA (USA) Visiting scientist at Berkeley Human Genome Center 1995- 1997: INSEAD-CEDEP program - Mana-gement of Strategic Alliances External Collabora-tions - (MBA-type training)1983-1986: Ph.D in Biochemistry: Microbio-logy University PVII, Pasteur Institute, Paris - Dr.C.Elmerich and Pr.J-P.Aubert), 1982-1983: Master (DEA) in Microbiology, Uni-versity Paris VII, Pasteur Institute 1979-1983: Engineer School, ESPCI PARISTECH Specialty in Chemistry, major of Specialty.

Industry background2015-present: VP, Head of the Roche Institute for Research and Translational Medicine, Roche SAS. July 2014-Dec.2014: Senior Partner and Co-founder, MedBiomiX Partner SASJanuary 2010 – July 2014: Senior Vice-President, Digital & Translational Sciences, IPSEN.February 2009 - December 2009: Senior Advi-sor, LINKS Conseil, Paris, France: February 2006 - February 2009: Chief Scientific Officer, GENETHON, Evry, France CSO, November 2004 - February 2006: Director, SANOFI-AVENTIS, Vitry and Montpellier, France Director, Onco-pharmacogenomics, Biomarker discovery and compound molecular MOA analy-sis (Oncology) 1999 – 2004: Director, Functional Genomics, AVENTIS, VitryFrance Director, Euro-pean Target Validation High Performance Unit 1997 – 1999: Director, Rhône-Poulenc Rorer, Evry-France Director, Evry, Genetic Center (Asth-ma, Cardiovascular, CNS (psychiatry, Parkinson’s disease)) 1996 – 1997: Director, RPR-Gencell, Santa Clara,

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Training and academic background2003-2005: Ph.D., Immunology, University of Toulouse, France 1998-2003: Doctor in Veterinary Medicine, Tou-louse National Veterinary School, France

Industry background2017-present: HOFFMANN-LA ROCHE AG – Ba-sel, Switzerland, Global Head, Oncology Biomar-kers• Overall responsibility for the development and implementation of the pRED Oncology Biomarkervision and strategy• Leader of a global Oncology Biomarker Team that is responsible for identification and valida-tion ofcandidate molecular biomarkers used for de-monstration of pharmacodynamic effects andmechanism-of action, as well as for response prediction and patient selection/stratification2015-2017: ITEOS THERAPEUTICS - Gosselies, Belgium , Director, Tumor Immunology• Project Leader for the best-in- class Adenosine A2a receptor antagonist EOS100xxx (undisclosed)• Project Leader for the IDO1 inhibitor PF-06840003/EOS200271 (entered Phase I in Sept 2016)2010-2015: PIERRE FABRE PHARMACEUTICALS, Head, Imaging and In Vivo Oncology; Immuno-

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Training and academic background2012-2016: Post Doctoral Fellow in Biology & Chemistry of radiotions, cell signaling and cancer Dep, Curie Institute, France, Project leader «Lea-ding of a scientific innovative project to study and develop new therapeutic strategies in the case of a pediatric brain tumor in mouse models 2007-2012: PhD in Biomedical Sciences; Phar-macologie, Biologie cellulaire et moléculaire, Uni-versity of René Descartes, Paris 5 2005-2007: Master of Neurosciences and Signa-lization, Paris IX University 2000-2003: Bachelor’s degree sciences, Behes-hti University, IRAN, Teheran 2015-2016: University diploma GBM (Biological and Medical Engineering) Innovation strategy in the biomedical companies and promotion of scientific research/ Analysis of needs of the bio-medical sector, market research and manage-ment risk, UPMC 2014/ 2015: Transfer of technology; Efficient gene transfer, in vivo cerebral electroporation/ technical training of international staff, Institute of Brain, School of Medicine, National Yang-Ming

success in highly complex diseases. We focus on a select group of diseases areas including onco-logy, hematology, neuroscience, immunology and inflammation, ophthalmology, infectious and rare diseases. Therefore, Personalized Health Care is key to improve patients’ daily life, to find the right treatment for the right patient. To achieve this ul-timate goal Diagnostics and Pharma are working together to find the right solutions.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


Roche is leading in cancer immunotherapy through advanced research, including immune profiling, with the goal to develop treatment tai-lored to individuals.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


At Roche, we are developing a great pipeline of new drugs targeting each step of the Cancer immunity cycle, including innovative approaches such as personalized cancer vaccines (based on neoepitopes to trigger specific antitumor immune responses) or bispecific antibodies.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


Our diverse approach to research and early development is carried out by five organizations: Genentech Research and early development - gRED (Genentech, in the United States, is a wholly owned member of the Roche Group and has been delivering on the promise of biotechno-logy for over 35 years), Roche Pharma Research and early development - pRED, Chugai Pharma-ceutical Co., Ltd., Japan (a member of the Roche Group), Foundation Medicine and our Diagnostics Division.

Roche’s partnering functions maintain close links to external organizations and we currently have partnerships and alliances with more than 200 external companies and institutes. gRED is loca-ted in South San Francisco (US), pRED is located in Basel (Switzerland), Schlieren (Switzerland), Penzberg (Germany) and Shangai (China). Chugai has three core research laboratories in Japan. Foundation Medicine is located in Cambridge (USA).

patrice DENÈFLEPh.D HDR, CEDEP INSEAD, Adjunct Professor Pa-ris Descartes - ParisTech Head, INSTITUT ROCHE for Research & Translational Medicine Roche S.A.S.

Gomes BRUNOD.V.M., Ph.DGlobal Head of Biomarkers OncologyRoche Pharma Research and Early Development

Shirvani HamassehPh.DScientist Project Manager

California, USA 1994 – 1996: Director, RPR-Gencell, Vitry, France Head of RPR-Gencell

ContactRoche S.A.S30, cours de l’île Seguin 92650 Boulogne-Billan-court, FranceM. +33 638 43 07 44

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Oncology - Experimental Oncology Research Center - Tou-louse, France2007-2010: Oncology SANOFI - Experimental Therapeutics and Translational Research - Vitry-sur-Seine, France

ContactRoche Innovation Center Basel F. Hoffmann-La Roche AGGrenzacherstrasse 124 (B.52, R.206) CH-4070 Basel, SwitzerlandT. +41 61 6885689M. +41 79 5637540

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

University, Taipei, TaiwanIndustry background2016-Present: Present Scientific Partnerships Project Manager Institut Roche, France - Scou-ting, implementation and scientific follow up of collaborative preclinical and translational projects with academic research lab in collaboration with pRED-Roche in Oncology and I3 (Immunology, Infectious Diseases and Inflammation) Areas of research interest Oncology (Immuno-Oncology, Targeted Therapies, Molecular Oncology,...), Im-munology, Inflammation.

ContactInstitut Roche for Research & Translational Medi-cine Tour horizons- Bureau 18M3Roche S.A.S.30, cours de l’île Seguin92650 Boulogne-Billancourt, FranceT. +33 (0)6 87 60 75 89M. +33 0(1) 47 61 41 95


IND

US

TR

IEL

S

Company name: SANOFICompany size: over 110 000 employeesR&D Staff: over 16 000 employeesNumber of countries: Over 100 countriesAnnual sales 2015: 37 billionR&D investment: 5.2 billion

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

COMPANY DESCRIPTION

Sanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs.

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of health care with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme.

Our ambition is based on four key strategic priorities: becoming a global healthcare leader with synergistic platforms, bringing innovative products to the market, seizing value-enhancing growth opportunities and adapting our company to future challenges and opportunities. With more than 110,000 employees in 100 countries, Sanofi and its partners act to protect health, enhance life and respond to the potential healthcare needs of the 7 billion people around the world.

For more information: www.sanofi.com - www.sanofi.tvSanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). For more details please visit our website www.sanofi.com.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


We are committed to becoming a long term par-tner to the Multiple Sclerosis community by wor-king to deliver scientific advancements that will have a significant impact on the lives of people living with MS.

Alzheimer’s and Parkinson’s diseases are the two most frequent neurodegenerative diseases. They affect approximately 27 million people world-wide, heavily impacting patients’ and caregivers’ lives and gradually lead to a loss of autonomy. The medical needs are still major, in particular, due to the absence of treatments preventing or slowing down the disease.

The ambition of our Research is to contribute to fighting these disabling diseases, in particular by preventing or delaying the disease progression, and to deliver innovative and high medical value solutions to patients.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


• Aubagio® (teriflunomide) is a prescription me-dicine used to treat relapsing forms of multiple sclerosis (MS).

• Lemtrada® (alemtuzumab) is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS).

• Riluzole (Rilutek, Teglutik) is used to slow the progress of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease).

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

PROSPECTIVE IN THIS AREA: THEMATIC PRIORITIES

• GLD52 (anti-CD52 mAb) - Relapsing multiple sclerosis (Phase I)

• Anti-protofibrillar AB mAb - Alzheimer’s disease (Phase I)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

SANOFI GENZYME

Sanofi Genzyme exists in France since 1994 and counts over 400 employees in total. The head-quarters are situated in Saint Germain en Laye (78), with teams throughout the French regions including activities in French overseas territories and in Lyon at the Polyclonal bioproducion site.

The plant is in the Gerland district in Lyon, the world renowned biotech cluster. The site pro-duces polyclonal antibodies preventing organ rejection in transplanted patients. This product is exclusively produced by Sanofi Genzyme in Lyon and is available in 68 countries worldwide.

Company name: SERVIERHeadquarters: SURESNES, FRANCENumber of countries: 148 countriesR&D investment: 25% of the turnover

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

COMPANY DESCRIPTION

Olivier Laureau, President of ServierWe are an international and independent phar-maceutical company governed by a non-pro-fit foundation, with headquarters in Suresnes, France. Since opening our first laboratory in 1954, we have been committed to therapeu-tic progress to serve patient needs with the help of healthcare professionals. We strive to provide future generations with a world where quality healthcare is available and accessible to all. Operating in 148 countries, we have 20.700 collaborators employed worldwide and a turno-ver of 4.152 billion euros in 2017. Entirely inde-pendent, we are able to reinvest 25% of our total revenue (excluding generics) into Research and Development, and all profits are used for further development. Corporate growth at Servier is driven by our continuous pursuit of innovation in five areas of excellence: cardiovascular and im-mune-inflammatory diseases, neuropsychiatric disorders, cancer and diabetes. We are a leading force in cardiology—number 2 in Europe, num-ber 8 worldwide—and oncology has become a top priority in recent years; we also manufacture high-quality generic drugs. Our three research centres are continuously involved in creating, testing, and developing new medicinal products, which are manufactured and packaged in our 16 production centres around the world. We have an active partnership policy in the field of biotechno-logy and we are investing in e-health through our internal WeHealth by Servier initiative. All our em-ployees are driven by shared values and guided by a common vision. Together we share the pas-sion of entrepreneurship and we are committed to therapeutic progress to serve patient needs. WITH 94 MILLION PATIENTS TREATED WORLD-WIDE BY OUR MEDICINAL PRODUCTS ON A DAILY BASIS, we are keenly aware of our responsibili-ties to patients, doctors, and healthcare profes-sionals. They are the motivating force behind our

daily drive for innovation as a provider of thera-peutic progress.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


At Servier, we believe that providing future gene-rations with a healthier world is the very essence of our mission. As a leading pharmaceutical com-pany, we work towards our purpose with passion, dedication, and determination.First and foremost, our conviction embodies pa-tient-centricity, as well as our code of ethics and compliance, our corporate social responsibility policy, and our endowment fund. We nurture indi-vidual and collective commitment by giving our employees a fulfilling and rewarding work envi-ronment conducive to creativity and innovation.• PATIENTS AT THE CENTER OF OUR WORK: Pa-

tients come first. They are central to each of our

activities, starting with the primary investiga-tive research of a molecular entity all the way to marketing the finished medicinal product.

• ETHICS: As a responsible healthcare provider, we are committed to promoting a culture of ethics and integrity in all our activities.

• COMPLIANCE: Compliance rules help each em-ployee act in accordance with the standards of integrity and ethics of the Group.

• CSR: We want the Servier Group to consistently be recognized as an involved healthcare pro-vider who makes positive and responsible contributions with the intention of preserving the future of all.

• SERVIER ENDOWMENT FUND: The Servier en-dowment fund is a core part of our social res-ponsibility approach and is a major component of our CSR strategy.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

PRODUCT PORTFOLIO IN THIS AREAServier’s Oncolgy products and R&D portfolio

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


Servier has the ambition to grow in Oncology by investing in innovative projects supported by academic collaborations and biotech partnershipMain areas of investment are in «Apoptosis» and «Immunotherapy».Both areas have been driven by innovation mind-set: the development of BH3 mimetics directed to different members of the BCL2 family and supported by a strong expertize in protein-pro-tein interaction (Kotschy A. et al, Nature. 2016 Oct 27;538(7626):477-482). On the immunotherapy side, Servier has been the 1st to invest in alloge-

nic CAR-T cell therapy (Preliminary clinical data from two phases I studies presented at ASH2017), opening potential to treat more patients.Area of research exploring both solid tumors and hematological malignancies:• Apoptosis: focus on the resistance of cancer

cells to programmed cells death• Immunotherapy: mobilization of T-cells against

tumors with allogeneic CAR-T cells and deve-lopment of next generation checkpoints (small molecules and biologics)

• Protein-Protein interactions: explore new high-potential targets

Servier is looking for innovative research and translational projects supporting main areas of investigation, as well as projects which could be complementary to current portfolio.


IND

US

TR

IEL

S

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

I have a 20-year industry experience, mainly in clinical trials management and global clinical development in Oncology. I have been working on trials from phase I to phase III across diverse tumor types but more specifically on RCC, Lymphoma and Breast Can-cer. I worked on the development of small mole-cules and antibodies. My experience ranges from operational study management to clinical programs overview; in-cluding 2-year professional experience in Japan. I am now supporting Servier’s business develop-ment as project director search and evaluation for oncology and participating to the establishment of a strategy for expanding Servier’s presence in Japan.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

I have a 20-year experience in cross-functional Management of Global Pharmaceutical Research & Development projects (innovation & early stage). I have experience in partnership mana-gement, including development / alliance mana-gement (5-year experience with Japan), and external opportunities evaluation for In licensing processes (Due Diligence).

I have a scientific background (PhD in Immu-nology) with a 7-year experience in academic research (INSERM, CEA) in Immuno-virology, neuro-immunology and auto-immune diseases; an 8-year experience in a CRO (Bertin pharma) as research projects Director in Immunological stu-dies ; and 6 years of experience at Stallergenes in Allergy Immunotherapy product development, portfolio and innovation management (Pharma-ceuticals & Diagnostics).

I’m currently at Servier’s Center for therapeutic innovation in Oncology, for search and evaluation of external opportunities for new R&D program in Immuno-oncology.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

I have a 5-years’ experience in immuno-oncology academic research at the Institut Curie. I had the opportunity to manage scientific and translational projects in close interaction with clinicians.

During my phD, I was also involved in a consulting mission to support public/private partnerships.I joined Servier 1 month ago to work as a scien-tific project leader within the external opportunity in oncology team.

Valérie AGRAPARTPharmD

Anne-Cécile RIMANIOLPhD

Anne-Marie GIVELPhD

PLACES OF WORLDWIDE INVESTIGATIONSClinical Operations around the world

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Lead Project Director Licensing Oncology BD&L ; SERVIER MondeBiologist by training with a PhD from the Univer-sity of Pierre & Marie Curie in Paris and a Master in biotech & pharma management from ESCP-EAP Paris. She has always been focused in the Oncology field, taking various positions from mar-keting, early drug discovery to scientific Business Development.

Joining Aventis, she was team leader for 8 years in oncology drug discovery projects, moving forward projects from target identification until preclinical candidate, major accomplishment was towards IGF1R project developing small molecule as well as antibody.

During 8 years within Sanofi Oncology Division, as director of oncology business opportunities, she was specialized in preclinical/discovery as-sets with an emphasis on oncobiologics including antibody drug conjugates. She has been playing a major role in building the following licenses and partnerships: in-licensing p53/mdm2, small mo-lecule inhibitor from Ascenta/Univ of Michigan; Dana Farber/Belfer Institute, strategic research collaboration; in licensing of antibody products for ADCs from Oxford Biotherapeutics; Caprion Target identification license & research collabo-ration; Algeta research collaboration for Thorium RadioImmunoTherapy; several technology deals to build ADC next generation (Innate Pharma BTG technology, Catalent SMART Tag technology, Glykos new linkers, Avipep small format). Within the Immuno-Oncology space the license and research collaboration with Innate Pharma for NK Cell Engagers.

She joined Servier, 2 years ago, to lead the onco-logy portfolio licensing activities within the BD&L department. Since here arrival at Servier, she has put in place the Pieris research collaboration and license agreement covering 8 imuno-oncology

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

External Research & Innovation in Immuno-Oncology – Center for Therapeutic Innovation in OncologyDr. Wurch completed a Ph.D in Molecular and Cellular Biology at the University Louis Pasteur (Strasbourg, FR, 1992), followed by a post-doc-toral training at the University of Ghent (BE). Back to France in 1994, he raised a molecular biology laboratory at the Pierre FABRE Research Center in Castres (FR). In 2003, he moved to the Centre d’Immunologie Pierre FABRE where he esta-blished a Molecular and Cellular Biology Depart-ment dedicated to molecular pharmacology and protein and antibody engineering. Since Septem-ber 2011, he leads the immunotherapy discovery research programs at the Institut de Recherches Servier. Since December 2016, Thierry is Director of the External Research and Innovation in Immu-no-Oncology at Servier.

He is currently member of the Editorial board of MABS Journal (Taylor & Francis) and Distin-guished Advisor of The Antibody Society. He is co-author of more than 90 publications.

In 2013, Thierry Wurch, was ranked #33 amongst the Top 50 global antibody industry influencers.

Corinne VENOTPhD, MBA

Thierry WURCHPhD, Director

bispecific anticalins, 2 research collaboration and license agreements on undisclosed targets with Vernalis and the WEHI, as well as a technology license with Transgene for CART Cell therapy.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


IND

US

TR

IEL

S

Company name: UCBCompany size: 7 500 employeesNumber of countries: Present in 40 countriesAnnual sales: $4,2 billion 2016R&D investment: NA

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

COMPANY DESCRIPTION

At UCB, we are inspired by patients and driven by science. We follow a single strategy: to offer value to people suffering from severe diseases in neurology and immunology. Founded in 1928 and headquartered in Belgium, UCB employs more than 7,500 people of 70 different nationalities operating in over 40 countries. Delivering patient value Rather than starting researching any new drug with the science alone, we want to better connect patients with science and science with patients. Better understanding the reality of patients living with neurological and immunological disorders will enable us to take a more holistic approach to care, ensuring that ultimately the right drug and the right care reaches the right patients in order for them to live the lives they choose.

Our business UCB is a global biopharmaceutical company, with a focus on neurology and immunology. Our busi-ness is strong. Total revenue grew to €4.2 billion in 2016. We are more than 7,500 people working in over 40 countries, inspired by patients and driven by science.

Looking ahead, we have a solid platform for conti-nuous growth with our core products Cimzia®, Vimpat®, Neupro®, Keppra® and Briviact®, and we are preparing the launch of Evenity® to help patients with osteoporosis and of our next wave of potential medicines to help patients with epile-psy and various arthritic conditions. At the same time, we are very excited about the progress in our early pipeline.

Driven by science Patients inspire us to bring them value through more cutting-edge science, more innovative drugs, and more practical solutions. Each year,

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Was previously leading BD and strategy at LFB. Joris is a former strategy consultant (Bionest Par-tners) and started his career as a scientist in the US (Arbor Vita Corporation) and the UK (UCB).

Joris is a trained Biotech engineer and holds a business and leadership degree from Harvard Business School.

more than a quarter of our turnover is reinvested in research and development. Based on clear priorities, we are well positioned to develop our molecules and deliver promising therapies. We have two state of the art R&D centers in Belgium and in the UK and several international partner-ships with renowned academic institutions. Our biological pilot factory in Belgium is fully opera-tional, and we recently inaugurated our biotech-nology production facility in Switzerland.

Joris Pezzini Head of Business Development Immunology& Bone

70 • LES RENCONTRES INTERNATIONALES DE BIOTECHNOLOGIES 2018

58, boulevard Gouvion-Saint-CyrCS 70073 - 75 858 Paris Cedex 17

T. : 33 (0)1 45 03 88 88

facebook.com/lemedicamentetmoi @LeemFrance

Leem LeemFrance

www.leem.org

27-31, avenue du Général Leclerc 94 710 Maisons-Alfort Cedex

facebook.com/bpifrance @bpifrance

Bpifrance

www.bpifrance.fr

Documents

LES RENCONTRES INTERNATIONALES DE BIOTECHNOLOGIES 20ov-leem.ovh › sites › default › files › RIB_Programm_2018_2.pdf · Bpifrance propose aux entreprises un continuum de financements